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1. INTRODUCTION  
Papillomavirus infections are common in both people and animals. Generally, 
these viruses may result in asymptomatic infections and can cause benign 
tumors as condylomas and papillomas in mucous membranes or warts and skin 
papillomas. However, in the case of persistent infections, these viruses may 
induce malignant tumors at various body sites. For a long time, papilloma-
viruses were considered as harmless viruses, but a discovery made by German 
virologist Harald zur Hausen put it them on par with pathogens responsible for 
deadly diseases. In 2008, the Nobel Prize in Physiology and Medicine was 
awarded to zur Hausen for his papillomavirus research. He was able to demon-
strate that human papillomaviruses (HPVs) can cause cervical cancers – the 
second-most-common cancers in women worldwide. HPV DNA replicates in 
the epithelial tissue, which is mostly composed of differentiating keratinocytes. 
HPV genomic DNA replication occurs in three clearly distinguishable phases, 
making the study and control of the virus complicated, because it is difficult to 
mimic all three stages of the virus infection cycle in the regular tissue culture 
cells under laboratory conditions.  
The first part of my thesis gives a general overview of papillomaviruses, 
their infection cycles and replication phases. Model systems widely used for the 
study of HPV biological functions will also be reviewed, and the topic of how 
recombination could be involved into HPV genome replication will be intro-
duced.  
The research part of my thesis will focus on using the human osteosarcoma 
cell line U2OS as a model system for studying the specific stages of genome 
replication of several types of HPV (Ref. I and II). We have demonstrated that 
head-to-tail oligomers (HPV DNA that contain several copies of the viral 
genome) are formed during HPV DNA replication (Ref. I and IV) and that two 
different mechanisms are involved in the HPV genome replication (Ref. IV and 
V), shedding new light on the events that occur during the different phases of 
papillomavirus DNA replication. Finally, I included an analysis of the 
papillomavirus and the Epstein-Barr virus’s segregation functions. Our data 
demonstrated that BPV1 E2 protein and minichromosome maintenance element 
(MME), or EBNA1 and FR dependent stable maintenance functions, are neces-
sary for the stable episomal multicopy nuclear replication of the plasmids with 
hybrid replication origin in different types of dividing cells (Ref. III). 
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2. LITERATURE REVIEW  
2.1. Introduction to Papillomaviruses 
Papillomaviruses (PVs) are a diverse group of viruses that infect keratinocytes 
of the epithelia, which serve as a barrier between the environment and internal 
organs of host. HPVs may have asymptomatic infections and do not cause clear 
clinical signs. They are usually eliminated from the epithelium by the adaptive 
immune system (Antonsson et al., 2000, Antonsson et al., 2003). Humans are 
often simultaneously colonized by several types of HPVs that cause subclinical 
infections in the skin and mucosa. Thereby, HPVs could be considered as a 
component of the normal skin microbiota that persists throughout people’s 
lives. However, certain HPV infections of the epithelia can have clinical mani-
festations ranging from hyperkeratotic lesions (small benign tumors, known as 
papillomas or warts) to malignant growth (e.g., cervical or anal cancers) (de 
Villiers et al., 2004, Clifford et al., 2003). HPVs account for more than 30% of 
all infection-associated cancers in humans (Zur Hausen, 2009).  
Currently, there are two commonly used HPV vaccines on the market. Both 
of them consist of recombinant purified, refolded structural L1 proteins, which 
form HPV type-specific virus-like particles (VLPs). None of the vaccines 
contain live attenuated viruses. The Gardasil and Cervarix vaccines are targeted 
against HPV6, HPV11, HPV16, HPV18 and HPV16, HPV18. HPV vaccines are 
preventive; they do not eliminate existing infection and have no therapeutic 
effect in diseases caused by HPV. Recently, a nine-valent vaccine was approved 
by FDA (Gardasil 9) (clinicaltrials.gov). The viral E6 and E7 oncoproteins are 
suitable targets for therapeutic vaccination. A multivalent HPV therapeutic vac-
cine candidate against six HPVs was reported (genticel.com); however, this 
vaccine is only in preclinical studies, so there is an urgent medical need for 
drugs that suppress HPV DNA replication.  
The nucleotide sequence of the capsid protein L1 gene is used to classify 
papillomaviruses because it appears to be the most conserved from coding 
sequences of these viruses. If the sequence coding for L1 differs from that of 
known viruses by at least 10%, the virus is classified as a new subtype (Bernard 
et al., 2010, Bravo and Félez-Sánchez, 2015). The family of Papillomaviridae 
has a long evolutionary history. PV DNA can be detected in a wide range of 
vertebrate species, including birds (Tachezy et al., 2002, Terai et al., 2002, Van 
Doorslaer et al., 2009) and reptiles (Bravo et al., 2010, Lange et al., 2011). 
Based on the structure of their skin, the most suitable hosts for these viruses are 
mammals (de Villiers et al., 2004, Bravo et al., 2010). According to recent 
information, the family Papillomaviridae contains 205 different PV types, 
which can be clustered into five genera: Alpha-, Beta-, Gamma-, Mu- and Nu- 
(α, β, γ, μ, ν) papillomaviruses (Bzhalava et al., 2015, Kocjan et al., 2015, 
www.hpvcenter.se). Most HPVs belong to α, β, or γ- papillomaviruses (de 
Villiers et al., 2004). Many mechanisms have governed the evolution of 
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papillomaviruses, including recombination between the viral and host genomes 
(Gottschling et al., 2007, Lazarczyk et al., 2009).  
HPVs are divided into cutaneous and mucosal types; the latter group  
(α-HPVs) is subdivided into high-risk and low-risk subgroups, based on the 
capacity of the viruses to cause malignant progression of the lesions. Low-risk 
HPVs such as HPV6 and HPV11 cause genital warts. Induction of cervical can-
cers are associated with the high-risk HPVs (16, 18, 31, 33, 35, 39, 45, 51, 52, 
56, 58, 59, 68, 73 and 82); three HPVs are classified as probable high-risk types 
(26, 53, and 66) (Muñoz et al., 2003). HPV16 infection causes not only cervical 
cancer but also vaginal, vulvar, penile and anal cancers (Al Moustafa et al., 
2014, Muñoz et al., 2006). A significant fraction of head and neck cancers are 
also caused by HPV16 and HPV18 (Betiol et al., 2013, Adams et al., 2014).  
β-HPVs have been associated with squamous cell carcinomas (SCC) of the skin 
(non-melanoma skin cancers) in immunocompromised and immunosuppressed 
individuals with the rare hereditary disease Epidermodysplasia Verruciformis 
(EV). HPV5 and HPV8 DNA have been detected in 90% of cutaneous SCCs in 
EV cases, and HPV5 DNA has been detected in primary tumors and metastases, 
suggesting a prominent role for HPV5 in SCC (Dell’Oste et al., 2009, Doorbar 
et al., 2012). β-HPV DNA has also been detected in non-melanoma skin cancers 
of immunocompetent non-EV patients (Boxman et al., 1997, Harwood and 
Proby, 2002, Purdie et al., 2005, Akgül et al., 2006, Nindl et al., 2007). The 
other PV genera, γ, μ and ν, comprise cutaneous HPVs that are usually linked to 
the development of cutaneous papillomas and warts (de Villiers et al., 2004). 
 
 
2.2. Papillomavirus virion and genome organization 
Papillomavirus virions lack a lipid envelope and are relatively small, approxi-
mately 55 nm in diameter (Doorbar, 2006, Favre et al., 1997). The PV genome 
is composed of ~8 kbp of double-stranded DNA (dsDNA) packed into nucleo-
somes by the histones. The DNA genome contains three major regions: a 
noncoding upstream regulatory region (URR), also-called a long control region 
(LCR), and two coding regions: an early region (E) and a late region (L) (Fig. 1).  
The URR region comprises viral and cellular transcription factors binding 
sites (Fig. 1) and is responsible for the control of PV gene expression (Doorbar, 
2007, Zheng and Baker, 2006, Bernard and Apt, 1994). β-HPVs have a shorter 
URR and different organization of regulatory sequences compared to α-HPVs 
and other genera (Reh and Pfister, 1990, Muller and Demeret, 2012). The URR 
of β-HPV contains a less easily identifiable binding site for the E1 replication 
protein. In addition, it has been shown that regulation mechanisms of the early 
promoter of α-HPV and β-HPV are different (Reh and Pfister, 1990, Horn et al., 
1993, May et al., 1994, Akgül et al., 2006). 
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Figure 1. (A), (B) and (C) Schematic representations of circular dsDNA genomes of 
high-risk α-HPV16, β-HPV8, and bovine papillomavirus type 1(BPV1), showing the 
location of the ORFs for early and late proteins and the URR region which contains the 
origin of replication, consisting of E1BS (E1 binding site) and E2BSs (E2 binding 
sites). The position of early and late promoters along with early and late 
polyadenylation sites are indicated. The minichromosome maintenance element (MME) 
of BPV1 is depicted in C. Figure A is adapted from (Kajitani et al., 2012). Figure B is 
adapted from (Lazarczyk et al., 2009). Figure C is adapted from (Skiadopoulos and 
McBride, 1998). Summary table (D) gives an overview of the basic functions of PV 
proteins and was adapted from (Bravo and Félez-Sánchez, 2015). 
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The early coding region contains open reading frames (ORFs) for PV proteins 
E6, E7, E1, E2, E4 and E5 (E5 is not present in β-HPVs) (Lazarczyk et al., 
2009). Early HPV proteins have regulatory functions and are responsible for 
oncogenic transformation of the host cells in the case of high-risk virus types.  
PV E1 protein belongs to the group of viral initiator-proteins. One well-
studied representative of this group is SV40 (Simian virus 40, family Polyoma-
viridae) large T-antigen (LT), which has certain similarities to E1 (Lambert, 
1991). There is much in common in the manner in which polyomaviruses and 
papillomaviruses use the cellular DNA replication mechanisms to replicate their 
viral genomes. Many research groups that study papillomaviruses DNA 
replication use the knowledge obtained from SV40 DNA replication to study 
the same aspects of papillomaviruses (Trowbridge et al., 1999, Simmons et al., 
1998, Hu et al., 2006, Archambault and Melendy, 2013). 
E2 protein is a transcriptional regulator of viral gene expression and a viral 
replication protein. It also provides a chromatin attachment (tethering) function, 
which helps maintain a stable copy number of viral episomes in dividing cells. 
We and others have shown that the truncated version of E2 protein, E8^E2, acts 
as a negative regulator of E2 and functions as a repressor of transcription and 
replication in β-HPVs (Sankovski et al., 2014). The same phenomenon has also 
been shown by others in α-HPVs (Stubenrauch et al., 2000, Kurg et al., 2010, 
Zobel et al., 2003). 
E6 binds the tumor suppressor protein p53 and promotes its ubiquitination 
and degradation. Protein E7 binds to several cellular tumor suppressor proteins, 
including the retinoblastoma protein (pRb), to modulate cell-cycle regulation. 
E6 and E7 activity promotes uncontrolled cell division (Zheng and Baker, 
2006).  
Late proteins of HPVs (L1 and L2) form the viral capsid and mediate pack-
aging of viral DNA into the virions (Buck et al., 2008). Other important func-
tions of HPV proteins are presented in the table that is included in Fig. 1D. 
 
 
2.3. Phases of the papillomavirus infection cycle 
The infection cycle (also known as the life cycle or replication cycle) of HPV is 
tightly linked to the differentiation program of the infected host cells, known as 
keratinocytes. Normal keratinocytes continuously stratify and differentiate, re-
newing the epithelium every two to three weeks. The cutaneous or mucosal 
stratified epithelium is separated from underlying tissues by the basement mem-
brane. Just above the basement membrane is the basal layer, which contains the 
only cells in the epithelium that can divide. When the cell divides, one of the 
daughter cells moves up to the suprabasal layer where the differentiation is ini-
tiated. This cell stops dividing and continues moving upward, replenishing the 
overlying cell layers that are lost because of desquamation (Kaur and Li, 2000).  
The PV virions enter basal keratinocytes through microwounds, targeting 
quickly dividing, transiently amplifying cells and/or slowly dividing stem cells 
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in the basal layer or in the hair follicles (Quint et al., 2015, Egawa et al., 2015, 
Schmitt et al., 1996). The receptors required for PV entry into cells are currently 
undefined. Possibly, PV entry requires the initial binding to heparan sulfate on 
the surface of basal cells; this initial binding is likely followed by association 
with a secondary receptor to allow virus entry (Conway and Meyers, 2009, 
Kines et al., 2009, Horvath et al., 2010, Schäfer et al., 2015).  
After virus entry into the host cell via endocytosis, L1 protein dissociates 
from the viral DNA and the genomic DNA is imported into the host cell nucleus 
(Surviladze et al., 2015, Bousarghin et al., 2003). Initial amplification of the 
HPV DNA of up to 50–300 copies per cell occurs (Garner-Hamrick and Fisher, 
2002, Maglennon et al., 2011). This relatively small number of HPV DNA 
copies per cell is likely sufficient for the virus to express enough early gene 
products while avoiding damage to the infected cell and triggering an immune 
response against the virus and infected cells (Evans et al., 2003, McKinney et 
al., 2015). Additionally, the low level of expression of early genes and the small 
number of HPV DNA copies might be caused by the presence of the cellular 
proteins inside the undifferentiated cells, which negatively regulate viral gene 
expression and may compete with viral proteins (E1 and E2) for binding to the 
viral origin of replication. 
Next, the papillomavirus genome establishes stable maintenance (latent 
infection) in the basal cells of the differentiating epithelium. Long-lasting latent 
infection is most likely connected with maintenance and replication of the PV 
genome in long-lived stem cells in this layer.  
 
 
 
Figure 2. (A) Changes in viral DNA copy number during the different phases of PV 
replication. (B) Normal and HPV-infected epithelia. Upon infection, the viral genomes 
are established in the host cell nucleus as low-copy episomes amplified with the help of 
viral replication proteins. Next, the viral genomes replicate in synchrony with cellular 
DNA replication (the maintenance replication period). Differentiation of HPV-positive 
cells induces the productive phase of the viral infection cycle, allowing vegetative 
amplification of the viral genome. In the late phase, L1 and L2 proteins are expressed 
and encapsidate newly synthesized viral genomes; virions are shed from the uppermost 
layers of the epithelium. Figure adapted from (Fisher, 2015). 
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At the productive stage of the virus infection cycle, the second amplification 
replication (also known as late or vegetative amplification) of the viral genome 
takes place. This occurs in the uppermost layer of the terminally differentiated 
keratinocytes and is associated with the synthesis of viral capsid proteins and 
assembly of viral particles. Finally, infectious PV particles are released from the 
remains of the host cell (Fig. 2B). 
For this study, it is crucial to understand the processes involving HPV DNA 
in infected cells. The various stages of replication of the virus genome will be 
reviewed next.  
 
 
2.3.1. Initial amplification replication of HPV DNA 
The replication of PV DNA is initiated at the origin of genome replication that 
binds virus-encoded replication factors: E1 and the full-length form of E2 pro-
teins (Del Vecchio et al., 1992, Ustav et al., 1993, Ustav and Stenlund, 1991). 
All other replication enzymes and proteins are derived from the host cells 
(Remm et al., 1992, Ustav et al., 1991). The host DNA-replication machinery 
includes DNA polymerase α-primase, DNA polymerase δ, RPA (replication 
protein A – the single-stranded DNA binding protein), PCNA (proliferating cell 
nuclear antigen), RFC (the replication factor C), topoisomerases and cyclin 
E/cdk2 (Chow and Broker, 2013, Kurg, 2011).  
E2 dimers bind to specific recognition sequences, short palindrome with con-
sensus 5’-ACCGNNNNCGGT-3’, called E2 binding sites (E2BSs). These ele-
ments are located in several positions in the PV genome (Steger and Corbach, 
1997, McBride et al., 1991) (Fig. 1A–C). The BPV1 genome contains 17 E2 
binding sites, 12 of which are located in the URR (Li et al., 1989) (Fig. 1C). For 
both α-HPV and β-HPV, the number of E2 binding sites is restricted to four in 
the URR, but the location and distribution relative to the viral promoters vary 
between α-HPV and β-HPV (Rogers et al., 2011). In the URR of α-HPVs, three 
sites (E2BS #1 to #3) are confined to the proximal region of the promoters 
(Doorbar, 2006) (Fig. 1A). The fourth site, E2BS #4, is located far from the 
others, upstream of the transcriptional enhancer (Demeret et al., 1997). At low 
concentrations, the E2 protein attaches to the most distal promoter, E2BS #4, 
which the strongest affinity; this binding activates the expression of early genes. 
When the level of E2 concentrations rise, the appropriate conditions for tran-
sient replication of HPV genome are created.  
When the levels of E2 protein become high, early gene expression is re-
pressed. This is caused by the overlap of the E2BSs with the binding sites of 
transcription factors TFIID and Sp1; therefore, the binding of E2 interferes with 
the binding of these transcription factors at the promoter (Demeret et al., 1997) 
(Fig. 1A). This regulation of viral gene expression may contribute to HPV DNA 
copy number control in undifferentiated cells. 
Binding of the E2 to the E2BSs, located adjacent to the E1 recognition 
sequence (E1BS), helps load E1 onto the origin (Berg and Stenlund, 1997). E1 
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alone binds weakly to the origin sequences; thus, complex formation with E2 is 
required (Sedman and Stenlund, 1995, Sedman et al., 1997). In the next step, E2 
dissociates from the complex, allowing the ATP-dependent assembly of E1 into 
double hexameric rings (Sanders and Stenlund, 1998, Titolo et al., 1999). The 
E1 hexameric complex has DNA helicase activity, which can unwind the DNA 
and initiate DNA replication (Schuck and Stenlund, 2005, Sedman and 
Stenlund, 1998). The E1 helicase also recruits host replication factors to the 
viral origin of replication (Skiadopoulos and McBride, 1998).  
Transient HPV DNA replication occurs in a bidirectional manner and leads 
to the formation of structures that resemble the Greek letter θ (theta) (Flores and 
Lambert, 1997). The theta model of replication was first described by the bio-
chemist John Cairns (CAIRNS, 1963). This replication mode is also a common 
for other small circular dsDNA viruses such as SV40. According to the theta 
scheme, replication of circular DNA genome begins at the origin of replication. 
DNA unwinding occurs and then two replication forks (RFs) assemble and pro-
gress in opposite directions. Expansion occurs along the circular genome until 
RFs converge opposite of the origin. Next, daughter molecules are separated 
(Fig. 3). In each fork, one strand (the leading strand) is synthesized con-
tinuously in the direction of the movement of the RF. The other strand (the 
lagging strand) is synthesized discontinuously in the opposite direction in the 
form of Okazaki fragments, which are later connected by ligations.  
Theta replication converts the parental circular dsDNA molecule into two 
daughter molecules, each of which has one strand from the parental DNA mole-
cule and a second newly synthesized strand (semiconservative synthesis). 
In addition to bidirectional replication, with two replicating forks moving 
away from the origin in opposite directions, there is a unidirectional mode of 
replication, in which one fork moves away from the other, which remains fixed 
at the origin of replication (Lilly and Camps, 2015, McKinney and Oliveira, 
2013). 
 
 
Figure 3. Theta replication is a type of replication common in E. coli (Escherichia 
coli) and other organisms possessing circular DNA.  
 
Determination of the mechanisms of HPV genome replication at the transient 
replication stage in the novel model system based on U2OS cells was one of the 
main topics of this thesis.  
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2.3.2. Stable maintenance of HPV genome replication 
Papillomaviruses may establish persistent infection in epithelial tissue. During 
the maintenance phase of replication, the viral genome is replicating in S phase 
in synchrony with the host genome DNA. The extrachromosomal viral genomes 
are tethered to the host genome by E2 protein during the mitosis, which pro-
vides the segregation function for the HPV DNA in dividing cells.  
The repressor protein E8^E2 could play an important role at this stage; 
expression of this protein could contribute to switching from the transient repli-
cation stage to persistent infection (McKinney et al., 2015, Stubenrauch et al., 
2000). 
Replication during the maintenance phase can occur in an ordered way, e.g., 
each episome replicates once per cell cycle, or randomly, whereby some 
episomes replicate several times and others do not replicate at all. The mecha-
nism of preference depends on the E1 levels in the host cell (Kadaja et al., 2009, 
Piirsoo et al., 1996, Hoffmann et al., 2006). As demonstrated by the examples 
of HPV16 and HPV31, viral DNA can replicate randomly or once per S phase, 
depending on the cell lines used. Thus, in the W12 cells, which are derived from 
a cervical lesion, HPV16 DNA replicates only once per S phase, but in another 
spontaneously immortalized human keratinocyte cell line, NIKS, HPV16 DNA 
replicates randomly (Hoffmann et al., 2006). However, these data should be 
further evaluated because the physical status of HPV16 DNA in the W12 clone 
used was not analyzed in that study. Integrated viral DNA, as demonstrated for 
HPV16 in W12 cells by Coleman and colleagues (Pett et al., 2006), must repli-
cate once per cell cycle. 
During the maintenance phase of replication, it is important for HPV to 
retain extrachromosomal genomes within dividing cells. Some viruses integrate 
their genome into the host genome, which promotes viral genome replication 
and segregation along with cellular DNA. For PVs, integration into the host 
genome terminates the viral infection cycle. Therefore, similar to the genomes 
of the Epstein-Barr virus (EBV) and human herpes virus 8 (HHV8), the 
genomes of PVs are usually not integrated into the host cell chromosome. 
During the viral latent phase, these viruses use an efficient mechanism that 
allows nearly equal distribution of episomes among daughter cells during host-
cell division by attaching the viral genome to the cell chromosomes using spe-
cific viral proteins (PVs-E2; EBV-EBNA1; HHV8-LANA1) and their special 
binding sites in the viral genome (You, 2010).  
However, the segregation functions of different types of PVs are different. 
All PVs distribute their genomic DNA through attachment to mitotic host 
chromosomes during cell division. The most-studied segregation mechanism is 
that of BPV1. This DNA attachment is mediated by E2 protein: its C-terminal 
DNA-binding domain is bound to viral DNA through the E2BSs at the URR, 
and the N-terminal transcription activation domain of the E2 is bound to the 
cellular chromatin (Kurg, 2011, Silla et al., 2005, Abroi et al., 2004). E2 is the 
only BPV1-encoded protein that is necessary and sufficient for chromatin 
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tethering of the plasmids, containing BPV1 URR via the E2 binding sites 
(Bastien and McBride, 2000, Ilves et al., 1999). The cellular receptor for BPV1 
E2 on mitotic chromosomes has been suggested as bromodomain protein 4 
(Brd4) (You et al., 2004). 
Segregation mechanisms of α- and β-HPVs have not been studied to a simi-
lar extent as BPV1. It is known that α-HPV E2 interacts weakly with Brd4. 
Additionally, it is assumed that various HPV Е2 proteins may attach the viral 
genomes to host chromosomes via different cellular targets (McPhillips et al., 
2006, Oliveira et al., 2006, Donaldson et al., 2007). Unlike E2 of BPV1, 
transcriptional activation and the Brd4-interacting domain of E2 of β-HPVs 
(e.g., HPV8) are not required for chromosome binding. In contrast to the 
dispersed and random pattern of binding to host chromosomes observed for E2 
of BPV1, E2 of HPV8 targets the short arms of acrocentric chromosomes. 
Furthermore, E2 of HPV8 interacts with the repeated ribosomal DNA units 
(rDNA) found in the same location. Accordingly, HPV8 E2-mediated genome 
tethering could occur using a Brd4-independent mechanism through novel 
interactions with specific regions of mitotic chromosomes (Poddar et al., 2009, 
Sekhar et al., 2010). Thus, HPV E2 proteins operatively bind with E2BSs and 
potential cellular proteins to interact with mitotic chromatin during segregation. 
 
 
2.3.3. Vegetative HPV genome replication 
When HPV infected basal cells divide, viral genomes are distributed between 
the daughter cells. One of these daughter cells detaches from the basal layer and 
moves towards the stratum granulosum. As soon as epithelial cells detach from 
basal layer, the cell cycle and division stop. Thus, because necessary cellular 
DNA polymerases and replication factors are produced only in mitotically 
active cells, HPVs should induce marked alterations in the biological activity of 
keratinocytes, affecting their differentiation. At this stage, HPV E6 and E7 play 
an important role. These proteins influence the cellular checkpoint mechanisms 
that ensure that the cell cycle is completed properly. E7 binds to retinoblastoma 
family members and promotes their degradation (Rashid et al., 2015), which 
induces unscheduled re-entry into the S phase. E6 prevents the induction of 
apoptosis in response to unscheduled S-phase entry through degradation of p53 
(Mantovani and Banks, 2001, Sherman et al., 1997). Thus, overexpression of E6 
and E7 can initiate neoplastic progression and, in vitro, immortalize primary 
human keratinocytes (PHKs), allowing the differentiating keratinocytes to begin 
uncontrolled proliferation and therefore supporting amplification of the viral 
genomes (vegetative phase of DNA replication) (Ganti et al., 2015, DeFilippis 
et al., 2003).  
The exact mechanism of PV genome vegetative amplification has not been 
described fully; however, there is some evidence that the mode of replication is 
different from that seen at the maintenance phase, i.e., replication might shift 
from the bidirectional theta model (Auborn et al., 1994) to another model – pre-
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sumably the rolling-circle replication (RCR) model (Flores and Lambert, 1997, 
Burnett et al., 1989, Dasgupta et al., 1992). Additionally, some recent studies of 
HPV DNA replication show that differentiation-dependent genome amplification 
activates the DNA-damage response (DDR) and repair-related pathways (Moody 
and Laimins, 2009, Fradet-Turcotte et al., 2011). This effect suggests that viral 
genomes might be amplified in differentiated cells by repair-related replication 
(Sakakibara et al., 2013). As a result, the viral DNA copy number amplifies from 
hundreds to thousands of copies per cell (Bedell et al., 1991).  
The late proteins L1 and L2 are produced in cells that reach the upper layers 
of the epithelium, where virion assembly takes place (Doorbar, 2006, Schwartz, 
2000).  
The infection cycle of HPVs is closely connected with the differentiation 
program of the host cells – i.e., keratinocytes – and infectious HPV virions can 
only be cultivated in special organotypic raft cultures containing a population of 
cells at various developmental stages, mimicking skin. 
 
 
2.4. Model systems to study the infection cycles of HPVs 
To create therapeutic antiviral drugs, it is important to understand the molecular 
mechanisms of HPV DNA replication; therefore, there is a great need for model 
systems that can mimic papillomavirus infection in humans. The following sec-
tion will give an overview of the model systems and techniques used to study 
various aspects of differentiation-dependent HPV genome replication at every 
step of the virus infection cycle. Several model systems are widely used. 
Because HPV cannot be propagated in the conventional way in monolayer cell 
cultures, other systems are used. Some use differentiating human keratinocytes 
to model productive infection in organotypic raft culture or through xenotrans-
plantation. These methods mimic in vivo infection but are technically complex 
and depend on the availability of human tissues. Animal models are also used 
because they can present with lesions similar to those found in humans. 
 
 
2.4.1. Epithelial cells 
HPVs infect the mucosal or cutaneous epithelium. For that reason, PV research 
tends to focus on epithelial cell differentiation. Some cell types are able to 
divide in vitro only a few times; others can persist for up to a hundred cell 
generations or indefinitely. Based on these differences, cultured epithelial cells 
can be divided into primary keratinocyte cell cultures and immortalized epi-
thelial cell lines. 
Primary cell cultures are cells that have been taken from a human or animal 
tissue (such as the kidney or liver) and transferred into culture conditions. Most 
of these cells are capable of limited growth in vitro for no more than five to ten 
division cycles. They are widely used in laboratory studies and for vaccine 
production. 
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Immortalized epithelial cells can divide indefinitely in vitro. Such “immor-
tal” cell lines usually originate from tumors or generate after introduction of 
mutations that make cells immortal. Often, because numerous successive trans-
formation steps take place during long cultivation, these immortal cells lose 
their similarity to the cells of origin. The most common indicator of such 
changes is the cells’ indefinite life span. 
Immortalized epithelial cell lines can be obtained from normal and tumor 
tissues of animals and humans. Immortalized epithelial cell lines derived from 
cervical carcinomas, such as SiHa (HPV16 positive), HeLa (HPV18), CIN-612 
(HPV31), CaSki (HPV16) and NIKS (HPV-negative), along with spontaneously 
immortalized human dermal keratinocytes (Adler et al., 1997, Allen-Hoffmann 
et al., 2000), are widely used in experimental virology. The great advantage of 
immortalized epithelial cell lines compared to primary cell cultures is that they 
can be propagated for an indefinitely long time by passaging cells at certain 
intervals.  
Some immortalized cell lines were adapted to grow in suspension culture. 
Such cultures are particularly useful in biochemical studies of viral DNA repli-
cation and in commercial vaccine production. Primary human keratinocyte cul-
tures derived from foreskin circumcisions are most frequently used to develop 
organotypic cultures (see below) (Henken et al., 2011, Blanton et al., 1991). 
Immortalized epithelial cell lines were used in early studies of animal 
papillomaviruses. The mouse fibroblast cell line C127 transfected with the 
BPV1 genome can support episomal viral DNA replication with a constant copy 
number (Law et al., 1981). These cells yielded the first data on PV replication 
cycles and have been used to study basic mechanisms and regulation of viral 
gene transcription and viral DNA replication (Berg and Stenlund, 1997, Neary 
and DiMaio, 1989). 
The HPV16-containing W12 model cell line of cervical squamous car-
cinoma has become a tool for studies of HPV replication cycle. At early pas-
sages in monolayer cultures, cells maintain HPV16 episomes at 100 to 200 
copies per cell (Stanley et al., 1989). The expression of E2 efficiently sup-
presses the transcription of E6 and E7 (Jeon et al., 1995, Romanczuk and 
Howley, 1992, Bechtold et al., 2003, Dall et al., 2008). Integration can occur at 
any time during episome maintenance. However, spontaneous loss of episomes 
occurs during long cultivation periods, resulting in cells containing only inte-
grated HPV16 (Pett et al., 2006). In cells containing integrated viral DNA the 
unregulated expression of the viral oncogenes E6 and E7 occurs because of the 
loss of E2, which represses viral transcription because the E2 ORFs are often 
disrupted during integration (Jeon et al., 1995, Romanczuk and Howley, 1992, 
Stanley et al., 2007). 
Not long ago, it was believed that most cutaneous β-HPVs have no trans-
forming properties. However, a group of researchers has demonstrated that 
HPV38 has in vitro transforming activity (Caldeira et al., 2003). That group has 
characterized several transforming properties of three cutaneous β-HPVs (10, 
20, and 38) and presented compelling evidence that E7 of HPV38 – but not of 
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HPV10 and HPV20 – induces loss of cell cycle control. The functions of 
HPV38 E6 and E7 appear to be more similar to those of the high-risk α-HPV 
oncoproteins. These data suggest a role for HPV38 infection in skin carcino-
genesis. 
The use of epithelial cells has made an enormous contribution to our under-
standing of the DNA replication of papillomaviruses and the paths that lead to 
cervical cancer. However, the full life cycle of the virus, which includes infec-
tion, DNA replication and persistence of the viral genome as an episome, can-
not be investigated in this model, because this system is not capable of progeny 
virus production.  
 
2.4.1.1. Induction of differentiation of epithelial cells 
In the epidermis, keratinocyte proliferation is restricted to the basal level. The 
cells eventually differentiate as they move up through the suprabasal layers 
(Fig. 2B). The differentiation of keratinocytes has been studied in models that 
include orthotopic and primary keratinocyte cultures. To simplify culture proce-
dures, many laboratories use monolayered primary cultures of keratinocytes. 
Most keratinocyte cell cultures can be directed to differentiation by placing 
them into suspension in methylcellulose (Green, 1977). Both high calcium 
concentration (Boyce and Ham, 1983, Berghard et al., 1990, Li et al., 1996) and 
cell confluency (Poumay and Pittelkow, 1995, Minner and Poumay, 2009) 
induce stratification and terminal differentiation of epithelial cells. These 
methods have been used in experiments with epithelial cells containing HPV 
genomes (Longworth and Laimins, 2004, Wilson and Laimins, 2005, Hong et 
al., 2011, Hebner et al., 2007, Donaldson et al., 2012). The advantage of these 
systems is the simplicity of the method and the reduced duration of the experi-
ment. Therefore, these techniques make it possible to study the interactions of 
host proteins with the virus and to determine those proteins’ role in the viral life 
cycle. This method might also prove useful for the study of chemical inhibitors 
affecting cell proliferation and screening for inhibitors of HPV DNA repli-
cation. Nevertheless, artificial differentiation of epithelial cells imposes certain 
limitations. Although late viral DNA amplification does occur, the progeny 
virus particles are not produced efficiently. Thus, some aspects connected with 
the viral production phase cannot be investigated in these models.  
 
 
2.4.2. Organotypic epithelial raft cultures 
Organotypic epithelial raft culture is one of the most promising in vitro models 
and is often used for the study of HPVs (Chow, 2015). Initially, organotypic 
epithelial raft culture was developed by dermatologists as a rapid method to 
obtain epithelial tissue for burn patients (Asselineau and Prunieras, 1984). 
Organotypic epithelial raft culture is the only in vitro system that can support 
full epithelial differentiation and enable reproduction of the entire life cycle of 
HPVs, from infection to the production of progeny virions (Dollard et al., 1992, 
24 
Cheng et al., 1995). However, for studying the HPV life cycle, this method is 
both time-consuming and expensive. First, collagen plugs are grown and epi-
thelial cells sown onto them. When the epithelial cells reach confluence, the 
submerged monolayer is transferred to a metal support grid and maintained at 
an air-liquid interface. Over the next two to three weeks, the cells stratify and 
differentiate, forming a full-thickness epithelium that produces differentiation-
specific cytokeratins (Ozbun and Patterson, 2014, Chow, 2015, Anacker and 
Moody, 2012). This technique can be used with primary human keratinocytes 
and established epithelial cell lines; it can easily be adapted for use with epi-
thelial tissues from normal or diseased biopsies (Grassmann et al., 1996, 
Henken et al., 2011, Dollard et al., 1992, Bedell et al., 1991).  
This technique was first used by Bedell et al. (Bedell et al., 1991) with the 
CIN-612 cell line, which was derived from a low-grade cervical lesion. They 
found that cells contained episomal DNA copies of HPV31 subtype. At the air-
liquid interface of in vitro raft cultures, this cell line differentiated in a way that 
histologically resembled a low-grade cervical lesion in vivo. The amplification 
of HPV31 genomes in the upper layer of the stratified epithelium was similar to 
that found in productive HPV infections in vivo. Unfortunately, although tran-
scripts from the late region of HPV31 were also detected in stratified raft cul-
tures, no capsid protein synthesis was found (Bedell et al., 1991). However, 
when Dollard et al. applied condylomas containing HPV11 DNA to raft cul-
tures, the epithelial cells underwent terminal differentiation and the full virus 
infection cycle took place, including virion assembly (Dollard et al., 1992). A 
later group of researchers from the University of New Mexico School of Medi-
cine used the raft system to generate large yields of viral-DNA-containing parti-
cles of HPV31b. They developed a biological homogenization system for virion 
extraction from raft epithelial tissues and described HPV virion production in 
the raft tissue-culture system from naturally infected cells (Ozbun, 2002a, 
Ozbun, 2002b). After the creation of a raft culture from naturally infected cells, 
publications have described the use of the electroporation-based system to 
create cell lines capable of stably maintaining episomal HPV18 and HPV45 
genomes and HPV virion production (Meyers et al., 1997, McLaughlin-Drubin 
et al., 2003). Despite the inability of low-risk HPVs to immortalize normal 
keratinocytes, organotypic epithelial rafts can be used for studies of their infec-
tion cycles (Thomas et al., 2001). 
Until recently, it was believed that most cutaneous β-HPVs have no trans-
forming properties. However, a group of researchers have demonstrated that 
HPV38 has in vitro transforming activity (Caldeira et al., 2003). They have 
characterized several transforming properties of three cutaneous β-HPVs (10, 
20, and 38) and presented compelling evidence that E7 of HPV38 – but not of 
HPV10 and HPV20 – induces loss of cell cycle control. The functions of 
HPV38 E6 and E7 appear to be more similar to those of the high-risk α-HPV 
oncoproteins. These data suggest a role for HPV38 infection in skin carcino-
genesis. 
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2.4.3. Animal models used to study HPVs 
A direct connection between PVs and cancer was first demonstrated in rabbits 
(cottontail rabbit papillomavirus, or CRPV), cattle (BPV) and dogs (canine oral 
papillomavirus, or COPV) at the end of the last century (Brandsma et al., 1991, 
Brandsma, 1994, Sundberg et al., 1986, Amtmann et al., 1984, Kreider and 
Bartlett, 1981). For many years, however, it was not known that some HPVs 
(HPV16 and HPV18) can be carcinogenic to humans. Experimental studies with 
animal papillomaviruses were a critical factor in this understanding. Animal 
papillomas were invaluable material in the investigation of viral biology, in the 
relationship between the virus and the host, in the immune response to the virus, 
and in the development of the first anti-papillomavirus vaccines (Campo and 
Roden, 2010). Animal PVs have been studied both as agents of disease in ani-
mals and as models for understanding HPV infection. In addition to the study of 
PV infection in animals, in vitro studies with animal PV proteins have con-
tributed greatly to the understanding of the mechanisms of cell transformation. 
 
2.4.3.1. BPV as a model system 
BPV1 has been an excellent model for the study of papillomaviruses; despite 
differences in genome organization and tissue tropism, it is also a useful model 
for HPVs. BPV1 E2 was the first PV factor to be identified as a transcriptional 
regulator (Spalholz et al., 1985, Yang et al., 1985). Moreover, BPV1 studies 
have shown the involvement of E2 in viral DNA replication (Ustav et al., 1991, 
Ustav and Stenlund, 1991, Ustav et al., 1993, Stenlund, 2003). BPV1’s asso-
ciation with mitotic chromosomes has been suggested as a mechanism for the 
segregation/partitioning of viral genomes between daughter cells (Abroi et al., 
2004, Lehman and Botchan, 1998, Ilves et al., 1999, Skiadopoulos and 
McBride, 1998).  
It has been shown that the early region of the BPV1 genome is sufficient for 
mouse cell transformation and that the virus genome is maintained as an 
extrachromosomal multicopy nuclear element, without the generation of viral 
particles (Lowy et al., 1980, Sarver et al., 1981, Uemura et al., 1992, Van 
Craenenbroeck et al., 2000). The early region is successfully used in the cloning 
vectors (Pavlakis and Hamer, 1983, Sambrook et al., 1985). The BPV1-based 
vector system enjoys the benefit of a long-term episomal persistence in the cells 
that express E1 and E2 proteins. These vectors contain a BPV1 minimal origin 
(MO) and the minichromosome maintenance element (MME), which consists of 
at least two E2 binding sites (Ilves et al., 1999, Ustav et al., 1993, Skiadopoulos 
and McBride, 1998). 
The optimal vector system that can be used in gene therapy should provide 
conditions under which the gene of interest would remain active at physio-
logically relevant levels for a long time period. The episomal vectors should 
have a high transfection efficiency and not integrate into the host cells (inte-
gration can modify the vector DNA or the DNA of the host cell or even cause 
oncogenic transformation). Because each virus-vector system has their strengths 
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and weaknesses, an effort has been made to create various hybrid vectors, 
designed to combine features of a variety of viral systems (Roberts and 
Weintraub, 1986). Such vectors are very useful in transient protein production. 
The hybrid episomal vectors can also be used during gene therapy to obtain a 
high level of expression of the gene of interest in the dividing cells over a long 
period of time; however, successful use of such vectors in humans remains to be 
demonstrated. 
Animal papillomavirus research was invaluable in understanding the nature 
of HPVs. Advances in molecular and cell-culture techniques have enabled 
scientists to shift their efforts from animal to human PVs. 
 
2.4.3.2. Transgenic mice 
Transgenic animals have been one of the most rapidly developing tools for 
papillomavirus cancer-related studies over the last 20 years. Many biomedical 
researchers have been focused on modeling human diseases both to study the 
pathogenesis and to search for new therapies. Transgenic models also enable 
easy detection of the effects of carcinogenic and other chemical agents. 
An animal model system can be used to mimic physiological processes that 
are also taking place in humans. One area in medicine and biology that makes 
the most use of transgenic mice models is oncology. The first transgenic mice 
with skin cancer were obtained using BPV1 (Lacey et al., 1986, Hanahan et al., 
1989, Sippola-Thiele et al., 1989, Lindgren et al., 1989). Numerous laboratories 
have also succeeded in engineering transgenic mice that carry the entire early 
region of HPV1 (Tinsley et al., 1992) or the E6 and E7 genes of HPV16 
(Kondoh et al., 1991, Arbeit et al., 1993, Lambert et al., 1993). 
As mentioned above, the links between skin cancer and the transforming 
activities of β-HPVs have not yet been fully characterized (Caldeira et al., 
2003). It is also believed that some cutaneous β-HPVs effectively inhibit apop-
tosis in response to UV (ultraviolet) damage by impairing DNA repair through 
E6 activity (Jackson and Storey, 2000, Akgül et al., 2005, Leverrier et al., 
2007). Studies performed on transgenic mice have confirmed the role of β-
HPVs such as HPV8 and HPV38 in the development of UV-induced skin can-
cer (Viarisio et al., 2011, Hufbauer et al., 2011). 
In addition to viral proteins E6 and E7, a major influence on the develop-
ment of HPV-caused cervical cancer is estrogen (Schneider et al., 1982, 
Swaneck and Fishman, 1988, Chung and Lambert, 2009, Auborn et al., 1991, 
Chung et al., 2008). The use of transgenic mice also helped shed light on estro-
gen’s effect on the development of cervical cancer.  
 
2.4.3.3. Xenograft model systems 
Mouse models of cancer are frequently used to search for new anticancers. 
Currently, patient-derived xenografts (PDXs) and cell-line xenograft models are 
used.  
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Cell-line xenograft models – i.e., human tumor cells that have been exten-
sively passaged in vitro – are injected into immunodeficient mice, resulting in in 
vivo tumor growth. Because of the simplicity and the relatively low cost of the 
technique, it is widely used. Another advantage is the wide range of available 
tumor types – i.e., explants (cell lines and tumor tissues of patients cultured in 
vitro). Although xenograft preclinical trials have been used to develop most of 
the recently used cancer drugs, this approach may be of uncertain value in pre-
dicting clinical efficacy in human patients (Voskoglou-Nomikos et al., 2003).  
Patient-derived xenografts are based on tumor tissue transplanted from a 
patient and directly injected into severe combined-immune-deficiency mice 
(SCID) (Clarke, 1996). Next, the tumor is transplanted from one mouse to 
another. Tumors can be implanted either heterotopically or orthotopically 
(Siolas and Hannon, 2013). Orthotopic transplantation more closely mimics 
human tumors than do models in which tumors have been obtained after multi-
ple passages in mice (Rubio-Viqueira and Hidalgo, 2009).  
 
 
2.5. The DNA-damage response during the papillomavirus 
replication cycle 
2.5.1. A short overview of DDR pathways 
Although DNA is relatively stable, many factors that can damage DNA are 
known, including internal factors such as replication stress, reactive metabolic 
intermediates and exogenous factors (e.g., chemicals, radioactivity and UV 
radiation) (Lindahl and Barnes, 2000, McKinney et al., 2015, Weitzman and 
Weitzman, 2014, Nakamura et al., 2014). Molecular mechanisms of the DNA-
damage response (DDR) include a network of dynamically interacting proteins 
and protein complexes, such as the MRE11-Rad50-Nbs1 complex (MRN) and 
the ATR-ATRIP complex formed by binding ATRIP to replication protein A 
(RPA). These complexes detect DNA damage and signal the need to stop the 
cell cycle while either eliminating damage to or inducing the death of damaged 
cells (Weitzman and Weitzman, 2014). The MRN and ATRIP complexes, 
which detect a wide range of DNA damage, recruit ataxia-telangiectasia 
mutated (ATM) and ATM and Rad3-related (ATR) serine/threonine protein 
kinases, which play a main role in these repair pathways (Lee, 2007). Both of 
those kinases act (in part) by controlling cell-cycle checkpoints at the G1, S and 
G2 phases (Turnell and Grand, 2012).  
ATR has broader functions in organizing the response to stalled replication 
forks and exposing single-stranded regions of DNA (Harper and Elledge, 2007, 
Cimprich and Cortez, 2008). The molecular mechanisms of ATR activation by a 
single-stranded DNA are fairly well known (Figure 4B) (Fanning et al., 2006, 
Cortez et al., 2001, Zhou and Elledge, 2000, Kumagai et al., 2006, Ohashi et al., 
2014, Lin et al., 2012, Shigechi et al., 2012). DNA repair is not the only role of 
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the DDR, which is also involved in cell-cycle regulation, arresting cell division 
until DNA repair is completed (McKinney et al., 2015, Stracker et al., 2009). 
Unlike single-strand breaks, dsDNA breaks are uncommon; however, they 
are one of the most serious types of DNA damage. The consequences of ATM 
activation are still debated. dsDNA breaks are bound by the MRN complex, 
which forms a bridge to the DNA gap and activates the ATM signaling cascade 
(Uziel et al., 2003, Bencokova et al., 2009, Moody and Laimins, 2009, Nikitin 
and Luftig, 2011) (Figure 4A). ATM promotes the repair of double-stranded 
breaks through homologous recombination (HR) (Noon et al., 2010).  
DNA-dependent protein kinase (DNA-PK) plays a central role in double-
stranded break repair (DSBR), regulating non-homologous end-joining (NHEJ) 
(Burma and Chen, 2004) (Figure 4C). 
 
 
 
Figure 4. DNA-damage response activation. (A) Activation of ATM-based signaling 
pathway. DSBRs are sensed by the MRN (Mre11-Rad50-Nbs1) complex, which attracts 
ATM and probably contributes to its activation. It is not well established how ATM is 
converted from its inactive to active conformation; one possibility is that it changes 
from an inactive dimer to an active monomeric form. (B) ATR activation. ATR is acti-
vated by ssDNA (single-stranded DNA), which can be derived either from resected 
DSB (left) or from stalled replication forks (right). RPA-coated ssDNA loads the 
ATRIP-ATR complex and the 9-1-1 complex (consisting of Rad9, Hus1 and Rad1), 
which brings together ATR and its allosteric activator TopBP1 (topoisomerase-binding 
protein 1 (C) Activation of DNA-PK-dependent pathways. DNA-PK comprises a large 
catalytic subunit (DNA-PKcs) and two regulatory subunits (Ku70 and Ku86). The Ku 
complex recognizes and binds to DSBs and then recruits and stabilizes the interaction of 
DNA-PKcs with damaged DNA. Two DNA-PKcs molecules, working in concert, tether 
DNA ends together in a synaptic complex and recruit the DNA ligase IV–XRCC4 com-
plex to rejoin the broken DNA ends. Figure adapted from (Lopez-Contreras, 2012). 
 
Over the last 20 years, many efforts have been made to characterize the relation-
ship between viral infection and DDR. Because infection with many viruses leads 
to DDR activation, the relationship between viral infection and DDR is of particu-
lar and increasing scientific interest (Turnell and Grand, 2012, Weitzman et al., 
2010, Nikitin and Luftig, 2011, Weitzman and Weitzman, 2014).  
DDR can be activated as a result of unusual structures of the viral DNA 
(linear or circular extrachromosomal molecules), unscheduled viral DNA syn-
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thesis, viral protein expression, or abnormal proliferation of infected cells. Some 
early studies revealed that viral DNA is recognized by the host cell as damaged 
DNA, possibly in an antiviral response directly targeting infection. Viruses, in 
turn, employ a complicated series of mechanisms to inhibit the activation of the 
cellular damage-response pathways. However, it remains unclear whether the 
activation of DDR is a by product of infection or a result of viral activity. The 
question of how viruses either avoid the cellular response or selectively activate 
DDR paths beneficial for them is a subject of significant interest (Edwards et al., 
2013, Weitzman et al., 2010, Nikitin and Luftig, 2011). Although the role of DDR 
in the virus infection cycle is well studied for some DNA viruses, the relationship 
between HPV and DDR should be examined more closely (Turnell and Grand, 
2012, Blackford et al., 2008, Baker et al., 2007, Cheng et al., 2011, Forrester et 
al., 2011, Orazio et al., 2011, Shirata et al., 2005).  
 
 
2.5.2. The activation of DDR during HPV genome replication  
The expression of HPV E1, E2, E6 and E7 proteins in undifferentiated primary 
keratinocytes and differentiated suprabasal epithelial cells leads to activation of 
the host ATR and ATM-dependent DDR signaling pathways. Moody and 
Laimins have shown that upon keratinocyte differentiation and viral episome 
amplification, the ATM kinase self-phosphorylates. Interestingly, the inhibition 
of ATM prevented episome amplification upon differentiation, but not the 
maintenance of HPV episomes in undifferentiated keratinocytes (Moody and 
Laimins, 2009). In other studies, it has been shown that over-expression of HPV 
E1 induced cell-cycle arrest and DDR activation in undifferentiated keratino-
cytes in the absence of viral DNA (Fradet-Turcotte et al., 2011, Sakakibara et 
al., 2011, Reinson et al., 2013).  
E1 expression is increased during the differentiation phase of epithelial 
cells, resulting in elevated replication of viral DNA. The HPV early protein E7 
binds to ATM and promotes Chk2-regulated, caspase-dependent activation of 
the HPV E1 protein (Moody and Laimins, 2009). We have previously demon-
strated that high-level expression of E1 from a heterologous vector system ini-
tiates replication from integrated HPV origins by multiple times in a single S 
phase (Kadaja et al., 2007). This replication can disrupt cell-cycle control in 
differentiating cells. Thus, repeated replication of HPV DNA and activation of 
the full ATM response becomes possible. 
HPV replication in differentiated cells occurs in nuclear replication foci 
(Sakakibara et al., 2013, Moody and Laimins, 2009, Turnell and Grand, 2012). 
Nuclear replication foci are so-called “replication factories,” i.e., specific 
regions in the nucleus that contain the components required for the synthesis of 
viral DNA. In these foci, the cellular DNA-damage response is induced and 
many markers of the ATM/ATR pathways are recruited. As mentioned above, 
the overexpression of E1 replication protein is sufficient to activate DDR; E1 
protein was shown to co-localize in the cellular replication foci with DDR 
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components (Sakakibara et al., 2011, Fradet-Turcotte et al., 2011, Reinson et 
al., 2013). It is likely that the virus mimics cellular DNA replication, including 
DNA-damage events, resulting in foci formation, attracting many DNA repli-
cation factors and repairing the damage. Thus, using DDR pathways, HPV can 
take advantage of cellular capabilities and resources for its own DNA repli-
cation. 
Another factor in DDR activation is changes in viral DNA amounts and 
structures in differentiated cells (Nikitin and Luftig, 2011, Sakakibara et al., 
2013). In the stable maintenance phase of the viral infection cycle, papilloma-
virus genomes might replicate in a bidirectional theta mode. However, the in-
creasing number of viral episomes can cause ATM activation, which is im-
portant for choosing the mode of replication (Moody and Laimins, 2009). 
Robust viral DNA replication through theta intermediates might generate nicks 
in the viral DNA, which may facilitate the switch from the theta mechanism to 
rolling-circle replication (Flores and Lambert, 1997, Kusumoto-Matsuo et al., 
2011, Auborn et al., 1994). BPV1 can also transition from bidirectional repli-
cation to unidirectional rolling-circle replication (Dasgupta et al., 1992, Burnett 
et al., 1989).  
Efficient replication is linked to a homologous recombination-related pro-
cess referred to as recombination-dependent replication (RDR) (Asai et al., 
1994, Kuzminov, 1999, Kogoma, 1996). Furthermore, we will show both that 
HPV genomes may use a unique recombination-related replication mechanism 
for multiplication of the viral DNA and that HPV genomic hetero-oligomers are 
formed through an RDR, not rolling-circle replication (RCR) (Orav et al., 
2013). It remains unclear how the transition from theta mode to recombination-
dependent replication occurs and how papillomaviruses use host recombination 
factors to recruit, engage, and manipulate viral DNA replication at various 
stages of the virus infection cycle.  
 
 
2.5.3. Pathways of dsDNA-breaks repair 
dsDNA breaks can be repaired either through homologous recombination (HR) 
or non-homologous end joining (NHEJ). NHEJ is the pathway in which two 
broken DSBs are sealed directly, without the need for homologous templates. 
DNA end ligation without preservation of the correct reading frame results in 
the loss of genetic information; for that reason, NHEJ can be prone to errors. In 
yeast, HR is the primary choice when repairing DSBs, whereas mammalian 
cells rely on NHEJ despite the higher probably of genomic instability. Never-
theless, NHEJ can occur in any stage of the cell cycle, which makes it simpler 
and faster than HR (Kee and D’Andrea, 2010).  
The high accuracy of HR pathways is provided by the exchange of DNA 
sequences between two similar or identical DNA strands. After a double-
stranded break occurs, sections of ssDNA around the 5’ ends of the break of one 
strand are excised in a process called resection. In the strand-invasion step that 
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follows, an overhanging 3’ end of the other strand is now formed as a result of a 
resection at one side of the DNA fragment. The ssDNA-binding protein RPA 
binds to 3’ overhangs and is later replaced by Rad51. Rad51, together with 
several other proteins, forms a filament. The Rad51 nucleoprotein filament 
searches for homologous sequences and mediates the formation of a displace-
ment loop (D-loop). A DNA polymerase then extends the invading 3’ and the 
D-loop structure is changed into an X-shaped structure called a Holliday junc-
tion (HJ). The 3′ strand of the second end serves as a primer for repair synthesis. 
(Fig. 5) (Krejci et al., 2012). 
 
 
 
 
Figure 5. DSB-repair mechanisms. (A) NHEJ. DSBs are sensed by the ring-shaped 
heterodimer Ku70/Ku80, which then stabilizes the two DNA ends and recruits DNA-
PK. Next, DNA-PK phosphorylates and activates the NHEJ effector complex (ligase 
IV/XRC44/XLF), which religates the broken DNA. (B) HR. The ATM kinase is 
recruited to a DSB via an interaction with the MRN complex. Once at the break, ATM 
becomes activated and phosphorylates multiple substrates. The DSBs that are resected 
form ssDNA strands. These ssDNA regions attract Rad51 and other associated proteins. 
The Rad51-coated nucleoprotein filaments then invade the undamaged sister strands, 
forming HJ structures. Figure adapted from (Lopez-Contreras, 2012). 
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The synthesis of D-loop intermediates can be classified into one of several path-
ways: synthesis-dependent strand annealing (SDSA), double-strand break repair 
(DSBR), or break-induced replication (BIR) (Stafa et al., 2014). Because 
possible replication modes of the HPV genome are a topic of this paper, we will 
consider the aspects of break-induced replication in more detail. BIR refers to 
recombination-dependent DNA synthesis initiated from one end of a DNA 
double-strand break; it can extend for more than 100 kb. The mechanisms that 
limit DNA synthesis during gene-conversion repair but promote extensive 
longer DNA synthesis in BIR remain unknown. Previous studies have shown 
that BIR can occur through either conservative or semiconservative DNA 
synthesis (Donnianni and Symington, 2013). Because a homologous DNA se-
quence is required for proper DNA repair, HR is restricted to the S and G2 
phases of the cell cycle, when homologous sister chromatids are present to pro-
vide a template. 
Figure 5 describes the two primary models of DSB repair, HR and NHEJ, 
both of which require multiple-step reactions. 
As previously noted, HPV DNA replication in differentiated cells occurs in 
so-called nuclear replication foci in which the MRN components are 
colocalized (Moody and Laimins, 2009, Reinson et al., 2013). Gillespie et al. 
have investigated the potential relationship between HPV genome replication 
and cellular repair pathways through HR (Gillespie et al., 2012). This group of 
scientists examined the levels of the cellular proteins involved in HR, including 
Rad51, BRCA1, pRPA, S33, concluding that they are also recruited to HPV 
replication foci, thus indicating the possibility that HR could be directly 
involved in HPV-genome amplification. 
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3. AIMS OF THE STUDY 
The diagnosis and treatment of diseases associated with HPV infections attract 
the attention of various experts because of the high level of infections by these 
pathogens in developing countries and the virus’s ability to transform epithelial 
cells, causing malignant pathology. Cervical and other HPV-dependent cancers 
are the result of a long chain of pathologic changes that can take place over 
many years of persistent HPV infection. There are no specific antiviral drugs 
against papillomavirus infections; therapeutic vaccines to treat persistent HPV 
infection are still under development. The goal of therapy should be the elimi-
nation of clinical and subclinical forms of HPV infection. 
There is a great need for model systems that can mimic papillomavirus 
infection in human tissues. To create new antiviral drugs, it is important to 
understand the molecular mechanisms of HPV DNA replication. The lack of a 
simple cellular assay system capable of supporting replication of multiple HPVs 
and mimicking the different stages of the viral infection cycle is a serious chal-
lenge for this research. 
 
The general objective of the research presented in this thesis was to generate 
and validate cellular assay systems, thus enabling the study of different repli-
cation phases of the papillomavirus genomes.  
 
The specific objectives of this research were as follows:  
1.  To develop and use a fast, efficient, reliable and cost-effective cellular sys-
tem based on the human osteosarcoma cell line U2OS and to demonstrate 
that this system is capable of supporting all three stages of the HPV genome 
replication cycle;  
2.  To study cutaneous and mucosal HPVs (both low-risk and high-risk) using 
the U2OS cell-line-based system and to analyze and characterize the physical 
state of HPV genomic DNA during various replication stages in those cells; 
3.  To analyze the replication intermediates of the HPV genome using one-
dimensional (1D), two-dimensional (2D) and three-dimensional (3D) 
agarose-gel electrophoresis (AGE) methods to identify the replication 
mechanisms, concentrating mostly on the first, transient replication phase in 
the U2OS cell-line-based model system; 
4.  To demonstrate that the segregation functions of various DNA viruses are 
principally interchangeable; to develop hybrid replication origins based on 
BPV1 and PyV, on the one hand, and EBV and PyV, on the other hand, 
thus allowing stable replication;  
5.  To demonstrate that hybrid origins provide stable multicopy nuclear repli-
cation functions to the therapeutic protein production vectors in the cells, 
which express all necessary viral trans-factors – LT (PyV) and E2 (BPV1) 
or EBNA1 (EBV) and can be used in the production of therapeutic proteins. 
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4. MATERIALS AND METHODS 
The materials and methods used during this study are described in detail in vari-
ous research articles and/or their supporting materials. However, some expla-
nations that aid in understanding this work will be presented below. 
Because one of the main purposes of my work was to develop a model 
system for HPV DNA replication studies that is based on the human osteo-
sarcoma cell line U2OS, this system will be discussed in more detail. 
The human osteosarcoma U2OS cell line was derived in 1964 from a 
moderately differentiated sarcoma of the tibia of a 15-year-old girl. It was one 
of the first cell lines generated and is frequently used in various areas of bio-
medical research. Two tumor-suppressor genes, p53 and pRb, are functional in 
U2OS cells (Wesierska-Gadek and Schmid, 2005, Isfort et al., 1995). 
Although osteosarcoma cell lines are not the natural host of HPV, U2OS 
cells support all replication stages of HPV genomes. We simulated the transient, 
stable, and vegetative stages of HPV replication by transfecting the U2OS cells 
with plasmids containing HPV genomes. In Ref. I, HPV genomes were excised 
from bacterial vectors pBR322 (HPV18, HPV6b and HPV5), pUC19 (HPV16 
and HPV11) or pUC9 (HPV8) and religated. In Ref IV and V, the technology 
for producing circular HPV genomes was changed. The minicircle parental 
plasmid pMC-HPV18 was constructed following insertion of the HPV18 
genome into pMC.BESPX the vector. Minicircle (plasmid lacking bacterial 
sequences) production was performed in the E. coli strain ZYCY10P3S2T 
based on the previously published protocol (Kay et al., 2010). DNAs almost 
perfectly corresponding to HPV18 genomes were then purified from E. coli as 
supercoiled minicircles and used to transfect U2OS cells. 
The papillomavirus infection cycle is closely related to the differentiation of 
the host cells. This step is supported by the fact that the vegetative amplification 
of viral DNA and the transcription of late genes occur only in differentiated 
suprabasal epithelial cells. In a keratinocyte culture that is dense or grown in a 
Methocell semi-solid medium, amplification of the viral genome is triggered as a 
result of the initiation of differentiation. To study HPV in the vegetative-amplifi-
cation stage, we used a simple system mimicking the differentiation of the epithe-
lium. Subclones were grown without splitting for approximately two weeks, and 
fresh medium was added every few days. Proliferation slows under these condi-
tions and the culture becomes dense over the next two weeks. However, the 
U2OS cells did not die. Because these cells harbored functional HPV genomes, it 
became possible to imitate all DNA replication steps. It should be mentioned, 
however, that the system remains limited because of the lack of expression of late 
proteins; moreover, there was no virion production. However, this limitation in-
creases laboratory safety while handling the cells because there is no risk of 
infection. 
We used 2D or 3D AGE to analyze the DNA replication products in Refs I, 
IV and V. During the first dimension of 2D neutral/neutral (N/N) gel electro-
phoresis, molecules are separated primarily according to their size (low agarose 
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percentage, low voltage and no ethidium bromide (EtBr) added). The strip of 
the agarose gel containing separated DNA is then cut out and oriented perpen-
dicular to the first dimension; a new gel with high agarose concentration is then 
poured around it. The second dimension is run at a high voltage in the presence 
of EtBr. Under these conditions, the molecules are separated according to their 
topology (conformation). 
The first dimension of 2D neutral/alkaline (N/A) gel electrophoresis is 
similar to the 2D N/N. Before the second dimension of electrophoresis, the gel 
was treated under alkaline denaturing conditions to separate the newly 
synthesized leading-strand DNA from the parental strand proportional to the 
length of the single-stranded chain. 
 
 
 
Figure 6. Schematic representation of the principles of 2D N/N, 2D N/A and 3D N/N/A 
AGE (N, nascent strand; P, parental strand; L, linear; NR, non-replicating DNA; EtBr, 
ethidium bromide; 1N, starting spot of the position (unit length); 2N, position at which 
the 1N molecules that were almost completely replicated would be expected to migrate 
(twice unit length); RI, replication intermediates). For more information, see Ref. V, 
Materials and Methods. 
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The first and the second dimensions of the 3D N/N/A gel electrophoresis were run 
in a manner that was identical to the 2D N/N analysis. The third dimension allows 
for the separation of nascent strands from the parental strands following their 
separation by size and topology in the first two dimensions (Fig. 6). 
The first dimension of 2D neutral/alkaline (N/A) gel electrophoresis is 
similar to the 2D N/N. Before the second dimension of electrophoresis, the gel 
was treated under alkaline denaturing conditions to separate the newly 
synthesized leading-strand DNA from the parental strand proportional to the 
length of the single-stranded chain. 
The first and the second dimensions of the 3D N/N/A gel electrophoresis 
were run in a manner that was identical to the 2D N/N analysis. The third dimen-
sion allows for the separation of nascent strands from the parental strands following 
their separation by size and topology in the first two dimensions (Fig. 6). 
The engineering of the hybrid vector system based on BPV1 and PyV repli-
cons, on the one hand, and EBV and PyV replicons, on the other hand, was one 
of the goals of this work. The mouse fibroblast cell lines COP5, which consti-
tutively express mouse polyomavirus T-antigens, were modified by inserting 
the cassettes for expression of the BPV1 E2 and EBV EBNA1 proteins 
(Ref. III).  
 
 
 
Figure 7. Schematic representation of the construction of PyV and BPV1/EBV hybrid 
origin. Constructs in which the PyV enhancer element is replaced by 10 E2 binding sites 
(MME) or the family of repeats element (FR), eukaryotic selection cassett (G418) and 
green fluorescent protein expression cassette (GFP or dEGFP) are shown. 
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The hybrid vector systems were designed by combining different viral cis-se-
quences. We replaced the PyV enhancer, which is part of the polyomavirus 
replication origin, with enhancer element from the BPV1 using the E2 protein-
dependent MME element (Fig 7). Alternatively, we used the Epstein-Barr virus 
EBNA1-dependent FR (family of repeats) element.  
We designed hybrid origin constructs (pMMEG, pMMEG* and pFRG*) 
that contain the expression cassette for the selection marker geneticin (G418). 
This is required for a long-term expression under selection of any gene of inter-
est. We also inserted green fluorescent proteins (either long-half-life EGFP or 
short-half-life d1EGFP) into the expression cassette, thus making it possible to 
test and follow the behavior of the hybrid origin construct inside the cells over 
time, for example, by using fluorescence-activated cell sorter analysis (FACS).  
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5. RESULTS AND DISCUSSION 
5.1. Model system to study the episomal maintenance  
of plasmids with hybrid origins (Ref. III) 
Genomes of papillomaviruses and the Epstein-Barr virus are maintained in the 
host cells as extrachromosomal plasmids. The stable maintenance of these 
viruses’ genomes depends on the viral cis-elements and trans-factors. Although 
a minimal origin (MO) is sufficient for transient BPV1 replication, stable extra-
chromosomal maintenance also requires the minichromosome maintenance ele-
ment (MME), which contains multiple E2 binding sites. Thus, MO and MME 
are cis-elements essential for BPV1-stable DNA replication. E1 and E2 are the 
only trans factors that are absolutely essential for papillomavirus DNA repli-
cation. An attachment of the papillomavirus genome to the host mitotic chromo-
somes occurs via E2, which binds both to the E2 binding sites in MME and to 
receptor protein(s) on the chromosomes. This would be a useful property for 
plasmid vectors designed for the long-term expression of proteins of interest. 
That said, vector systems based on the BPV1 platform have some dis-
advantages. One of the reasons that the BPV1-based vector systems were not 
widely used is that it is very hard to achieve the initial high levels of amplifi-
cation of such vectors in transfected cells. Another reason is that the papilloma-
virus replication protein E1 can cause dsDNA breaks, thereby activating a cel-
lular response to DNA damage (Reinson et al., 2013, Van Craenenbroeck et al., 
2000), which is a disadvantage for vector systems. Therefore, we tried to solve 
these issues by generating the hybrid replication origin. 
For the hybrid system, the mouse polyomavirus (PyV) replication origin 
and a virus-encoded replication factor, large T antigen were selected. PyV is a 
lytic virus and PyV origin-containing plasmids replicate very rapidly during 
productive infection. Therefore, PyV-based vector systems can efficiently repli-
cate the foreign DNA in permissive cells. There was no need to use wt-origin 
(enhancer and minimal origin) in cis and Large-T helicase in trans during the 
vector system development, because they usually tend to overreplicate and dis-
rupt the establishment of stable maintenance. Therefore, the enhancer of 
polyomavirus replication origin was removed and only the minimal origin that 
is able to initiate replication in the presence of LT was used. Furthermore, the wt 
enhancer of PyV was replaced with either an artificial enhancer element from the 
BPV1 or an FR-element from the EBV (Materials and Methods, Fig. 7). 
The plasmids pMMEG, pMMEG* and pFRG* (Ref. III, Fig. 6A; Materials 
and Methods, Fig. 7) with hybrid origins were transfected into the 
COP5E2/Puro or COP5EBNA1/Puro cells, which stably express the PyV LT, 
BPV1 E2 and EBV EBNA1 proteins. These cells were able to support the effi-
cient transient replication of hybrid origin plasmids. Because the vectors 
expressed enhanced GFP (EGFP), the replication was detected using the 
Southern blot method and flow cytometry. Transfected cells were grown in 
continuous culture in the presence or absence of Geneticin for up to 96 days. 
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The percentage of the cells expressing GFP was measured every second day 
throughout the experiment. 
The percentage of GFP-expressing cells under selective conditions rapidly 
reached its maximum level (approximately 90%) and was stable during the pas-
saging of cells for more than three months. The percentage of cells expressing 
destabilized enhanced GFP (d1EGFP) under selective conditions was somewhat 
lower, in the range of 40 to 70% (Ref. III, Fig. 6B, C and D). To test the hybrid 
system in the absence of selective pressure, a medium without antibiotic was 
used. As expected, under these conditions the percentage of EGFP and d1EGFP 
positive cells started to decrease. Over 55 days, the percentage of EGFP-con-
taining cells dropped precipitously, from 90% to 1% in the case of pMMEG 
(from 64% to 2.4% in 37 days in the case of pMMEG* and from 40% to 1% in 
30 days in the case of pFRG*) (Ref. III, Fig. 6B, C and D). When G418 selec-
tion was restored, the percentage of EGFP and dEGFP-positive cells was also 
restored to their previous high level over 10 days (Ref. III, Fig. 6B, C and D).  
Thus, under nonselective conditions, the percentage of the reporter protein-
positive cells began to decrease. The reasons for the loss of fluorescence may be 
different, for example, inactivation of the promoter used to drive the expression 
of EGFP. To find out the reasons for the loss of fluorescence, both plasmid 
DNA content in cells and FACS were analyzed. After removing the selection 
and taking FACS measurements every second day, total DNA was extracted. 
Total DNA analysis shows an increased amount of cellular DNA that is 
coherent with the growth of the culture (Ref. III, Fig. 7). Because this coincided 
with decreased EGFP fluorescence, it was concluded that in these cells, the 
EGFP-expressing plasmids were not integrated, but resided as episomes. The 
addition of selection pressure contributes to episomal rescue. The fact that the 
number of episome (EGFP) positive cells under nonselective conditions is 
gradually reducing in the cell population might indicate that the episomes are 
not distributed evenly into the daughter cells, thus leading to the gradual re-
duction of the percentage of plasmid-positive cells. 
To analyze this process, the rate of loss was calculated for each plasmid. To 
characterize the kinetics of loss, a first-order reaction (λ) = (−1/t)(ln Nt/N0) was 
used, where N0 is the percentage of fluorescent cells at the beginning of the 
experiment and Nt is the percentage of luminous cells after t generations. The 
rate of loss during one cell generation of plasmids containing hybrid origin was 
approximately 6% (pMMEG, pMMEG*) and 13% (pFRG*) (Ref. III, table 1); 
this was much lower than for control plasmids (pEGFP-C1 and pd1EGFP-N1) 
that did not contain hybrid origin of replication, at –22–33%. These data sug-
gest this replicating system is suitable for use even without selection. 
This study also revealed that EBNA1/FR elements and E2/MMEs confer 
comparable segregation/partitioning functions on the plasmids containing 
hybrid PyV origin in the analyzed cell models. 
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5.2. U2OS cell line as an in vitro model system to study 
various stages of HPV DNA replication (Ref. I and II) 
As reviewed in Section 2.4, many different model systems are used to study 
papillomaviruses. Each assay system has strengths and weaknesses; by effi-
ciently combining them, we can obtain a complete picture of the nature of the 
virus infection cycle. HPVs are strictly epitheliotropic and are generally active 
in keratinocytes. This term is often restricted to cells derived from squamous 
epithelia or, even more specifically, to cells from epidermis that express keratin 
(columnar and simple epithelia). At each stage of their differentiation, keratino-
cytes express specific keratins (e.g., keratin 1, keratin 5, keratin 10 and keratin 
14), along with other differentiation-specific markers such as involucrin, loricrin, 
transglutaminase, filaggrin and caspase 14 (Del Bino et al., 2004, Ekanayake-
Mudiyanselage et al., 1998, Tu et al., 2012). 
Because the replication modes of HPV genomes are host cell differentia-
tion-dependent, for a long time there were no efficient, easy-to-use cell systems 
for studies of HPV DNA replication. Artificial skin models such as raft cultures 
can be used to study the spatial distribution of HPV late functions within a 
differentiated epithelium, but they are time-consuming, not very reliable and 
prone to variability. We have developed and examined the utility of an alter-
native simplified system for the rapid analysis of early and late stages of HPV 
DNA replication. 
Although appropriate cell culture systems supporting HPV DNA replication 
are limited, the replication of papillomavirus-origin-containing plasmids could 
be easily reconstituted in many cell types of various species expressing the viral 
replication proteins E1 and E2 from heterologous expression vectors. Such results 
suggest that the regulated expression of the viral replication proteins from the 
HPV genomes could restrict HPV genome replication to certain cell types. 
We analyzed the ability of several immortalized or transformed human cell 
lines (C33A, 293, HaCaT, HeLa, SiHa, U2OS) to support the E1- and E2-de-
pendent replication of HPV-origin-containing plasmids. Although most of the 
human cell lines analyzed supported this type of DNA replication, one cell line, 
U2OS, was remarkably more efficient than others. We observed that U2OS 
efficiently supports the replication of HPV-origin-containing plasmids, even at 
low concentrations of viral replication proteins. Next, the recircularized full-
length HPV genomes were introduced into these cells by electroporation, and 
we were able to demonstrate efficient viral DNA replication in U2OS cells in 
transient assays. 
The goal of this part of the work was to demonstrate the suitability of the 
U2OS cells for studying the replication of genomes of various HPV types. 
U2OS is derived from a moderately differentiated osteosarcoma, has an 
adherent epithelial morphology and carries the wild-type pRb and p53 genes. 
The main advantage of the U2OS cellular assay system over keratinocyte-based 
systems is that, as we learned, U2OS can support replication of not only α-HPV 
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(high-risk HPV16, HPV18 and low-risk HPV6b, HPV11) genomes but also  
β-HPV (HPV5, HPV8) genomes.  
We have been able to show that this cellular assay system has a unique 
capacity to support the transient, stable and late amplification of HPV genomes 
(Ref. I). Moreover, compared to organotypic raft cultures or xenograft models, 
this system is simple, easy and safe to use. Thus, it can be applied in conditions 
that are suitable for automated industrial use, such as developing vaccines and 
antiviral drugs or screening HPV-replication inhibitors.  
Another important point of this model system is that the transcription maps 
of HPV18, HPV5 and HPV11 genomes replicating in U2OS cells (Toots et al., 
2014, Sankovski et al., 2014, Isok-Paas et al., 2015) are similar, if not identical, 
to the transcription maps obtained from HPV-infected human keratinocyte raft-
culture systems (Wang et al., 2011, Chow et al., 1987). These observations con-
firm that the gene-expression profiles of different high- and low-risk α-HPVs 
and of β-HPVs in U2OS cells are similar to HPV gene expression patterns in 
their natural environment (undifferentiated keratinocytes). Therefore, we be-
lieve that U2OS system can be used to study the fundamental properties and 
functions of HPVs. 
 
 
5.2.1. Initial HPV genome amplification in the human U2OS cell line 
The early-gene products E1 and E2 are necessary for the initiation of HPV- and 
BPV1-genome replication either in transformed cells or in primary keratino-
cytes (Hubert and Laimins, 2002, Lace et al., 2008, Ustav and Stenlund, 1991, 
Chiang et al., 1992, Frattini and Laimins, 1994, Sverdrup and Khan, 1994). 
Even without feeder cells, the U2OS cell line efficiently supports the replication 
of HPV URR-containing plasmids given that viral replication proteins are addi-
tionally expressed from independent expression vectors. Moreover, U2OS cells 
can support viral genome replication without the need for the cotransfection of 
plasmids used for E1 and E2 expression, indicating that sufficient expression 
levels of E1 and E2 are achieved directly from the viral genome. Cutaneous 
high-risk α-HPVs (HPV16, HPV18), low-risk α-HPVs (HPV6b, HPV11) and 
mucosal β-HPVs (HPV5, HPV8) were chosen for analysis. By transfecting 
U2OS cells with different recircularized DNAs representing HPV genomes, we 
demonstrated efficient replication (Ref. I, Fig. 1A, B, C, D). These results sug-
gest that all of the analyzed HPV types can trigger the expression of viral repli-
cation factors from viral promoters at a level sufficient to initiate replication of 
the viral genome in U2OS cells.  
Additionally, these observations provided us with an opportunity to study 
various aspects of the HPV life cycle, including the transcription and segrega-
tion functions of HPV genomes using U2OS monolayer cultures. Importantly, 
for the first time, U2OS cells provided us an opportunity to study the behavior 
of mucosal β-HPV genomes in monolayer cultures.  
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To confirm that α-HPV genome replication is completely dependent on the 
expression of viral E1 and E2 and that these proteins are essential for the initia-
tion of viral genome replication in U2OS cells, we generated a set of mutant 
genomes (described in Ref. I, Materials and Methods, and Ref. I, Fig. 3H, line 1 
for scheme). More specifically, we created a subgenomic construct of HPV18 
lacking the genes that encode the L1 and L2 proteins. Because the viral origin 
and the ORFs of early proteins are intact, this genome truncation does not affect 
transient DNA replication (Ref. I, Fig. 1E, lanes 1, 2). We also generated 
several mutant genomes of HPV18 (wt or subgenome context), which are defec-
tive for expression of the E1 or E2. Defects in the E1 ORF (Ref. I, Materials 
and Methods, mutations in the OliI and BcuI restriction sites) and E2 ORF (Ref. 
I, Materials and Methods, mutations in the StuI site) eliminated the capability of 
the mutated HPV18 subgenome to replicate in U2OS cells (Ref. I, Fig. 1E, 
lanes 9 and 10, 15 and 16, and 5 and 6, respectively). However, when we 
cotransfected the E1- and E2-defective recircularized genomes/subgenomes 
with the HPV18 E1 or E2 expression vectors, respectively (Kadaja et al., 2007), 
replication was restored (Ref. I, Fig. 1E, lanes 7 and 8, 13 and 14, 19 and 20, 
and 25 and 26). In addition, replication competence could be restored by 
cotransfecting the E1-defective genomes with E2-defective ones, thus demon-
strating the complementary functions of both replication proteins (Ref. I, Fig. 
1E, lanes 11 and 12, 17 and 18, and 23 and 24).  
Similar experiments were conducted with the β-HPV5 genome. E1- and E2- 
defective mutant genomes, which are unable to replicate, were generated (Ref. 
II, Fig. 1A, lanes 4–9). Again, because of the complementation of the genetic 
defects, cotransfection of these defective genomes resulted in the restored repli-
cation capability of both mutant genomes (Ref. II, Fig. 1A, lanes 10–12). Taken 
together, these experiments indicate not only that E1 and E2 are both necessary 
for initiating the replication of the mucosal and cutaneous HPV genomes in 
U2OS cells but also that for both of these HPV groups, the two defective viral 
genomes can complement each other’s defects.  
 
 
5.2.2. Stable replication of the HPV18 genome in U2OS cells 
Both our success in the initial replication of six types of HPV genomes in the 
U2OS cell line and the fact that the replication signal increases over time sug-
gested that HPV genomes remained in these cells and underwent stable repli-
cation. To analyze the stable episomal maintenance stage, we cotransfected 
HPV18, –16, –11, –6b, –5 and –8 genomes with the plasmid containing a selec-
tion marker. Next, a subset of the cells was maintained without the addition of 
G418 to the medium, and another subset was grown in the presence of anti-
biotic. Three weeks later, geneticin-selected cells were separated and subcloned. 
Additionally, the geneticin-selected cell pools and cells grown without anti-
biotic were analyzed using low-molecular-weight (LMW) cellular DNA 
extracts (Ref. I, Fig. 2A). A Southern blot analysis showed that all of the 
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samples contained HPV genomes at comparable levels. These data indicate both 
that U2OS cells support the stable replication of all types of analyzed HPV 
genomes and that HPV-transfected cells were efficient at maintaining viral 
DNA even under nonselective conditions (Ref. I, Fig. 2A, lanes 1, 3, 5, 7). 
The cell pools, which were grown under antibiotic pressure, were subcloned 
(from the single-cell colonies) and cultivated. Total DNA was extracted from 
every HPV-type cell sample and analyzed. As indicated by the Southern blot 
(Ref. I, Fig. 2C), the viral-DNA copy number in different cell clones ranges 
from low to high. Interestingly, the variance in the HPV DNA copy number was 
much greater in α-HPV-positive subclones than in β-HPV-positive subclones. 
The next stage of the stable HPV DNA replication study was to assess the 
long-term, stable persistence of HPV genomes in U2OS cells. HPV-positive 
subclones were regularly passaged for at least two months. Every week, total 
cellular DNA samples were taken and analyzed by Southern blotting (Ref. I, 
Fig. 2D). This analysis revealed that majority of HPV subclones was stable in 
U2OS cells. In particular, high-risk HPV18 subclones such as 18#1.13 and 
18#1.4 maintained HPV genome extrachromosomally and only some subclones 
(such as 18#1.10) showed HPV18 DNA integration into the host genome. The 
high-risk HPV16 subclones also maintained HPV16 DNA stably, with the 
exception of subclone 16#3.3, which demonstrated a loss of episomal copy 
numbers over time. The low-risk α-HPVs and β-HPV subclones showed a lower 
rate of establishing the maintenance of viral genomes compared to high-risk α-
HPVs. Thus, we observed not only a rapid loss of the viral genome in some 
low-risk HPV subclones (Ref. I, Fig. 2D, 6b#41) but also integration (Ref. I, 
Fig. 2D, 11#3.13).  
 
 
5.2.3. HPV-genome amplification in confluent cell cultures 
As mentioned above, the infection cycle of HPV is tightly linked to the 
differentiation program of keratinocytes. The final phase of the HPV replication 
cycle is vegetative amplification, in which the viral genome is actively repli-
cated and the HPV DNA copy number increases multiple times. In natural 
infection, capsid proteins (L1, L2) are synthesized during the vegetative phase 
to enable virion assembly. However, in high-risk HPV-positive keratinocytes in 
monolayer cultures (see 2.4.1.1), various methods used to induce differentiation 
have managed to achieve HPV-genome amplification only; no late proteins 
synthesis can be detected. 
By keeping the cells under confluent conditions, we decelerated the cell 
division and imitated the start of vegetative amplification in HPV-positive 
U2OS subclones to analyze the induction of HPV-genome amplification. Sub-
clones from various HPV types were seeded onto plates at fixed subconfluent 
densities and grown for 12 days without splitting; the media were exchanged in 
every two days (Ref. I, Fig. 3C and G). Measurement of the viral DNA copy 
number at various point in time revealed that the copy number increased over 
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time, imitating the start of vegetative amplification. Quantification performed 
for the HPV18 subclone 18#1.13 showed an approximately 10-fold increase in 
the amount of HPV DNA per cell in the confluent culture at day 12 (Ref. I, Fig. 
3D). Amplification of the DNA of other HPV subtypes was also achieved under 
the confluent culture conditions (Ref. I, Fig. 3G). Perhaps, in mimicking the 
conditions of cell differentiation, we have created conditions for the viral 
genome that allowed a second amplification of viral DNA. The cell-growth 
graph (Ref. I, Fig. 3A) demonstrates that after reaching confluence, cell division 
slows down, which is probably a prerequisite for the virus to generate more 
viral DNA copies per cell. 
One additional method to confirm HPV DNA amplification in confluent 
culture conditions is FISH (fluorescence in situ hybridization) analysis, which 
was performed on interphase cells. Samples of HPV18 subclone 18#1.13 were 
collected from subconfluent and confluent conditions. HPV genomes localized 
into a few fixed spots in the nuclei of proliferating cells. Maintenance of the 
cells under confluent culture conditions induced the increase in the amount of 
HPV DNA at these sites (Ref. I, Fig. 4), thus confirming the results obtained 
from the Southern blot analysis. 
Amplification of the DNA of low-risk HPVs was not as efficient, and only 
one out of six analyzed β-HPV subclones, 5#23, demonstrated a slight tendency 
to amplify viral DNA in confluent cell culture (Ref. I, Fig. 3G 5#23; Ref. II, 
Fig. 1C, D). Additionally, it was found that the HPV5 late promoter was acti-
vated in confluent U2OS cells; however, we were unable to identify late 
polyadenylation cleavage sites for the late transcripts (Sankovski et al., 2014).  
 
 
5.3. Concatemerization of HPV genomes (Ref. I, IV and V) 
Using the U2OS cell line as a cellular assay system to study the DNA repli-
cation of α-HPV low- and high-risk and β-HPVs, we have shown, that these 
cells efficiently support the replication of various HPV genomes during initial 
transient amplification, stable replication and late amplification, which was 
reminiscent of vegetative replication. 
Next, we explored the physical state of HPV DNA during various repli-
cation stages in U2OS cells. We used 1D analysis of uncut DNA fractions from 
HPV18-transfected cells (Ref. I, Fig. 5A, Ref. IV, Fig. 1C) and uncut DNA 
from HPV18 subclone 18#1.13 (Ref. I, Fig. 5B). An analysis of low-molecular-
weight HPV DNA showed not only that replication signals accumulated over 
time but also that dimeric and higher oligomeric forms of HPV genome 
appeared at later points.  
Moreover, these oligomers are efficiently maintained in proliferating HPV-
positive U2OS cell lines during multiple passages (Ref. I, Fig. 5A, lane 2–3, 4–
7 and Ref. I, Fig. 5B, lane 2–6). The role of the oligomeric state of DNA in the 
HPV life cycle is unknown. HPV18 oligomeric genomes might have an 
advantage in maintenance over monomeric genomes. We assume that oligo-
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merization could be a viral mechanism to assemble a set of maintenance, 
segregation, and partitioning functions to achieve an advantage by retaining the 
maximal number of DNA copies during the stable maintenance phase in the 
condition under which the expression levels of viral replication proteins E1 and 
E2 remain low. 
 
 
5.3.1. HPV genomic oligomers are extrachromosomal concatemeric 
molecules containing the viral genome in a head-to-tail orientation 
Next, we used the U2OS cell-based assay system to characterize oligomeric 
forms of HPV genomes. First, we applied restriction analysis (Ref. I, Fig. 5C 
and 5D and Ref. IV, Fig. 2A) and digested HPV DNA from an HPV18-positive 
subclone 18#1.13 with three different linearizing enzymes. Oligomeric forms 
present in the undigested DNA (Ref. I, Fig. 5C and 5D, lane 1, 2, 6, 7) were cut 
into single-unit-length linear fragments with all three linearizing endonucleases 
(Ref. I, Fig. 5C and 5D, lane 3–5, 8–10; Ref. IV, Fig. 2A, lane 1–4). This 
simple experiment demonstrates that the multimeric genomes are head-to-tail 
concatemers (the multiple copies of the HPV DNA sequences are not randomly 
oriented within the concatemer but instead are all oriented in the head-to-tail 
form).  
Second, to support the previous conclusion, a partial digestion analysis was 
performed. As expected, the results showed that the oligomeric HPV genomes 
were organized as head-to-tail episomal concatemers (Ref. IV, Fig. 2B). We 
also found that oligomerization does not depend on the topology of the input 
DNA (Ref. IV, Fig. 1A and B), nor does it require any other viral factors in 
addition to the replication proteins E1 and E2 (Ref. I, Fig. 1E; Ref. IV, Fig. 
3B). We have also shown the oligomerization of HPV18 and HPV11 genomes 
in the SiHa, HeLa and C33A cell lines, all of which were derived from cervical 
carcinomas (Ref. IV, Fig. 7). 
The DNA of HPV in patient samples is often present as genome multimers 
(Adachi et al., 1996, Cullen et al., 1991, Kalantari et al., 2001, Kristiansen et al., 
1994, Lehn et al., 1988). We also demonstrated the presence of oligomeric HPV 
genomes in clinical samples obtained from HPV-infected patients. (Ref. IV, 
Fig. 8). These data suggest that HPV genome oligomerization is common for all 
in vivo HPV infections. The existence of oligomeric episomal HPV genomes 
has also been previously demonstrated for HPV16 in the W12 cell line (Alazawi 
et al., 2002) and for HPV31 in the CIN612 cell line (Hong and Laimins, 2013).  
These results indicate that oligomerization is a natural process in HPV-
genome replication; it does not occur only in U2OS cells. Accordingly, we can 
conclude that oligomerization during the HPV infection cycle in our model 
system mimics the oligomerization process during HPV infection in keratino-
cytes. 
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5.3.2. HPV replication-dependent genome oligomers  
arise through homologous recombination 
Head-to-tail oligomeric molecules may be a product of various mechanisms 
associated with DNA replication. First, oligomers are generated through RCR 
that uses a single molecule as a template. RCR can generate long concatemeric 
linear molecules that consist of the same type of monomeric units. Thus, RCR 
products are obligatory homo-oligomers, and hetero-oligomers cannot be 
obtained in this manner (Fig. 8A). The second possible mechanism, RDR, takes 
place between two separate molecules (Fig. 8B). The head-to-tail oligomeric 
molecules generated through this process therefore might be not only homo-
oligomers but also hetero-oligomers.  
 
 
 
Figure 8. A schematic representation of the formation of homo- and hetero-oligomers. 
The formation of homo-oligomers can be obtained from rolling-circle replication (A) 
and the bidirectional theta-replication (B); hetero-oligomeric molecules can be only a 
product of homologous recombination. RDR refers to recombination dependent 
replication. 
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Cotransfection of U2OS cells with two different replicating HPV plasmids (8-
kbp wtHPV18 genomic and 5.4-kbp HPV18E subgenomic construct) allowed 
us to demonstrate that during HPV DNA replication, hetero-oligomers can be 
generated (Ref. IV, Fig. 5B, lines 5–8; Fig. 8). Hetero-oligomers can also be 
obtained through the cotransfection of an HPV18 genome with a URR-
containing plasmid (Ref. IV, Fig. 4E). 
Homologous RDR is the only replication mode that can create oligomers 
between different homologous but not identical HPV molecules. Based on these 
results, we suggest that observed DNA oligomers may be produced through this 
process. 
 
 
5.4. Identification of replication intermediates arising 
during the initial HPV genome amplification (Ref. I and V) 
5.4.1. Topology of HPV genomes in U2OS cells 
To examine the topological forms of HPV DNA replication intermediates (RI) 
in U2OS cells more thoroughly, we used neutral-neutral two-dimensional 
agarose gel electrophoresis (AGE). Analysis of the uncut forms of DNA RIs 
using 2D AGE facilitates the separation of linear, open circular (OC), and cova-
lently closed circular (CCC) molecules (Ref. I, Fig. 5F-H). These figures repre-
sent the RI patterns of undigested HPV18 18#1.13 DNA both from the stable 
assay (Ref. I, Fig. 5F) and from vegetative amplification (Ref. I, Fig. 5H). As 
expected, we detected signals that are interpretable not only as the oligomeric 
forms of the genome but also as signals from the monomeric episomes in both 
the CCC and OC forms. 
The development of a U2OS-based transient replication assay has enabled 
us to study early HPV DNA replication events in a time-dependent manner. To 
trace the appearance of oligomeric forms of HPV18 genomes over time, U2OS 
cells were transfected with HPV18wt minicircles. The results of 2D AGE (Ref. 
V, Fig. 1A) confirmed the data obtained through 1D analysis indicating that 
oligomers become more prevalent over time (Ref. I, Fig. 5A).  
Recently, it has been shown that the HPV18E8– mutant does not produce 
the E8^E2 repressor protein, resulting in a much stronger replication signal at 
earlier time points (Kurg et al., 2010, Reinson et al., 2013). Nevertheless, we 
could not detect qualitative differences in replication patterns between 
HPV18wt and HPV18E8– genomes by 1D and 2D analysis (Ref. V, Fig. 1A and 
C). In addition to the signals from linear, OC and CCC molecules detected for 
uncut samples from HPV18wt transfected cells, signals characteristic of bidirec-
tional theta-replication intermediates are clearly visible for similarly treated 
samples from HPV18E8– genome transfected cells (Ref. V, Fig. 1C, marked 
with a bold arrows).  
The works of Martín-Parras, Belanger, Cohen and others demonstrate that 
RCR intermediates form a so-called eyebrow-shaped signal during 2D N/N gel 
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electrophoresis (Cohen et al., 2005, Martín-Parras et al., 1998, Belanger et al., 
1996). However, we cannot detect that type of classical long RCR signal in our 
experiments (Ref. V, Fig. 1C). Instead, some related shorter RIs could be seen 
as horizontal lines connecting several structures; although their appearance 
becomes more intensive in a time-dependent manner and seen even in the 
wtHPV18 case, the exact nature of these molecules is unclear. 
 
 
5.4.2. Two different populations of molecules arise during  
the HPV genome transient replication 
As demonstrated in chapter 5.1, all three phases of HPV DNA replication can 
be studied using the U2OS model system. Transient HPV DNA replication 
closely mimics that occurring in the early phase of the HPV infection cycle, 
thus representing the initial amplification phase of viral DNA replication. The 
episomal DNA extracted from HPV18E8–-transfected U2OS cells three days 
post-transfection (Ref. V, Fig. 3A) and five days post-transfection (data not 
shown) was linearized with either BglI, Bpu1102I, XmaJI or PsyI and analyzed 
via 2D N/N AGE (Materials and Methods, Fig. 6, native conditions). We chose 
restriction endonucleases that cleave the plasmid only once at positions dis-
tributed throughout the HPV genome (Ref. V, Fig. 3C). 
Digestion of circular HPV molecules with BglI or Bpu1102I (corresponding 
recognition sites are located close to HPV origin) produces a diagonal arc ini-
tiating near the 1N spot of unreplicated or replicated HPV18 DNA. This diago-
nal line represents RIs, with two opposite-direction converging replication forks 
(RFs) (usually toward the termination site located approximately 180° from ori) 
arranged such that cleavage with these enzymes opens the bubble (Ref. V, Fig. 
3A, BglI and Bpu1102I, marked with a black arrow). In the analysis of the 
results of restrictions on XmaJI and PsyI, enzymes that cut opposite the origin, 
the appearance of specific arcs indicates the presence of “bubble” intermediates 
in these fragments (Ref. V, Fig. 3A, XmaJI and PsyI, marked with a black 
arrow).  
There was also an accumulation of molecules with high molecular mass and 
branched topology in every case (Ref. V, Fig. 3A, marked with a black arrow-
head). Because these molecules migrate at the end of the signal representing the 
dY intermediates, they may represent nearly fully replicated, late theta inter-
mediates; however, the exact nature of these linked molecules remains unclear. 
Despite the use of different restriction enzymes, one pattern, in addition to 
that of the one interpreted as corresponding to theta RIs, did not change (Ref. V, 
Fig. 2A and 3A, marked with a white arrows) and became more intense over 
time (Ref. V, Fig. 2A, marked with a white arrows). These novel signals repre-
sent molecules that could not arise during the bidirectional theta-replication of 
monomeric HPV genomes.  
The analysis of the uncut samples isolated from U2OS cells transfected 
with HPV18E8– minicircles indicated that bidirectional theta-replication might 
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also be initiated from dimeric HPV genomes (Ref. V, Fig. 1C, marked with a 
white arrow). The bidirectional theta-replication of dimeric HPV genomes with 
only one active origin of replication was expected, after BglI digestion, to result 
in simple Y-shape RIs (in principle, similar to Ref. V, Fig. 2B, simple Y inter-
mediates). However, the obtained migration pattern of these novel molecules 
did not resemble the migration pattern characteristic of simple Y molecules 
(Ref. V, Fig. 2A to 2B). The migration pattern of these novel molecules with 
regard to the migration pattern of theta RIs did not change upon alteration of the 
conditions used for the 2D N/N AGE (Ref. V, Supplementary Fig. 1S). Because 
the novel RI does not have common features and characteristics with the inter-
mediates of bidirectional replication, we suggest that a second mechanism is 
involved in the replication of the HPV18 genome. 
In our 1D study, we demonstrated that the formation of oligomers of HPV 
genomes increases over time (Ref. I, Fig 5A, Ref. IV, Fig 1C). To prove that the 
new, supposedly second mode of HPV DNA replication is associated with the 
formation of oligomers, we purified and linearized HPV DNA from U2OS cells 
at late time points 144, 168, 192, 216 and 240 hours (data not shown). It was 
observed that the pattern of theta-replication became less prominent or com-
pletely disappeared at later time points and novel or secondary RI became much 
more prominent. This indicates that the switch into the next mode of HPV DNA 
replication could be taken place at later time points in the transient replication 
assay. A similar switch has been described by Flores and Lambert for differen-
tiation-dependent HPV16 and HPV31 genome replication (Flores and Lambert, 
1997), but they interpret their data as theta-replication being replaced by RCR. 
This may be because those authors only analyzed the RI from small fragments 
of the genome; thus, their results may have been misleading. In contrast, 
because we conducted 2D AGE with the whole genome, we did clearly observe 
that our second replication intermediates could not originate from RCR (Ref. V, 
Fig. 3A). 
To exclude the possibility that the second mechanism of replication of the 
HPV18 genome could occur only in U2OS cells, we repeated experiments in 
HaCaT cells (spontaneously immortalized human keratinocyte cell line) that 
have been widely used for studies of skin biology and differentiation. НаСаТ is 
an HPV-negative cell line that can support the replication of the HPV18E8– 
genome, albeit with much lower efficiency than U2OS cells (Ref. V, Fig. 7). 
Nevertheless, the analysis of RIs in НаСаТ cells revealed the presence both of 
dY molecules representing the intermediates of bidirectional theta-replication 
(Ref. V, Fig. 7, marked with a black arrow) and of the intermediates of the 
second replication mechanism (Ref. V, Fig. 7, marked with white arrows). 
These results indicate that analogous replication intermediates are not specific 
to U2OS cells. 
We also conducted a restriction analysis of viral DNA isolated from HPV-
positive subclones of U2OS cells at the amplification stage. HPV18 subclone 
18#1.13 was seeded on plates at fixed subconfluent densities and grown for 12 
days without splitting while media were exchanged every two days. Next, the 
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DNA was extracted and linearized with numerous restriction endonucleases that 
cleave the HPV genome only once at positions distributed throughout the HPV 
sequence, and the RIs were analyzed on 2D gels (data not shown). As a result, 
we obtained RI patterns similar to those seen during the initial amplification of 
the HPV genome. Although the theta-replication pattern could not be seen, the 
second replication mechanism was clearly dominant, indicating that at the later 
time points of HPV DNA replication, the second mechanism, most likely 
homologous RDR, is more prevalent.  
 
 
5.4.3. Analysis of nascent strands during  
the initial amplification of HPV genomes 
In addition to bidirectional theta-replication intermediates, we can see signals of 
unknown origin on images obtained from 2D analysis. These new RIs retained 
the same migration pattern in all experiments regardless of which type of 
restriction enzyme was used (Ref. V, Fig. 3A, marked with a white arrows). To 
better understand the nature of these replication signals, we used the 3D N/N/A 
AGE method (Ref. V, Fig. 3B). Using this method, it is possible to separate 
nascent and parental strands after the second dimension (Fig. 6; Ref. V, Fig. 
3D). As a result of this experiment, we found that in the secondary replication 
mechanism, the chains were separated, confirming that the previously observed 
molecules are indeed intermediates of DNA replication. The nascent strands of 
the second RIs form a single arc containing molecules that are continuously 
increasing in length (up to the length of the parental strands). According to the 
schematic image (Ref. V, Fig. 3D), the migration pattern of nascent strands 
originating from this second replication somewhat resembles the migration 
pattern of simple Y molecules. However, as we see from Ref. V, Fig. 3A 
(marked with a white arrows), the arcs of these molecules from the second 
replication do not begin at the 1N molecule, thus rendering uncertain the con-
clusion that the molecules are Y-shaped. In other words, the secondary repli-
cation arcs move somehow unexpectedly. 
To ensure a better understanding of the mechanisms of HPV DNA repli-
cation, we used the neutral/alkaline (N/A) 2-dimensional method. In this assay, 
the alkaline second dimension allows separation of newly synthesized leading-
strand DNA from the parental strand. 
For this analysis, we first digested isolated LMW DNA with XmaJI or BglI. 
The restriction fragments obtained using XmaJI contain an origin of replication 
approximately in the middle (bubble RI). Alternatively, in the case of digestion 
with BglI, theta RIs appeared in the form of dY intermediates (Ref. V, Fig. 4D). 
Nascent-strand-migration models originating from different RI types during the 
2D N/A gel electrophoresis are depicted in Ref. V, Fig. 4A (Nawotka and 
Huberman, 1988). To facilitate the interpretation of data obtained by N/A analy-
sis, the second dimension of N/A AGE was performed in parallel with the 
second dimension in N/N neutral conditions. The results were aligned based on 
the migration progressions in the 1D analysis (Ref. V, Fig. 4B and C). 
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As we can clearly see, the N/A analysis of samples isolated from U2OS 
cells that were transfected with HPV18E8– minicircle DNA digested with line-
arizing restriction enzymes revealed the presence of bidirectional theta-repli-
cation intermediates (Ref. V, Fig. 4B and C, marked with a black arrows). In the 
case of cleavage with BglI, theta-replication resulted in dY or converging fork 
intermediates and XmaJI digestion resulted in bubble intermediates. These data 
are coherent both with the results obtained using N/N-analysis and with the 
scheme depicting the migration patterns formed by nascent strands originating 
from theta-replication during 2D N/A gel electrophoresis (Ref. V, Fig. 4A). 
Simultaneously, another arc of the nascent strands is present (Ref. V, Fig. 
4B and C, marked with a white arrows, N/A). This arc is a continuous Y or 
asymmetric dY-shape (Ref. V, Fig 4A) that eventually reaches the size of the 
parental strands, suggesting unidirectional replication. 
However, the intermediates of the novel HPV-replication mechanism 
yielded a signal that was initially (closer to 1N) similar to the arc of nascent 
strands originating from the replication-bubble intermediates (Ref. V, Fig. 4A). 
As an additional confirmation, during the analysis of the XmaJI digestion, the 
signals representing nascent strands originating from bidirectional theta-repli-
cation and the second replication mechanism partially overlapped, which is a 
strong indication of shared characteristics (Ref. V, Fig. 4C, N/A, marked by 
black and white arrows).  
The fact that RIs do not originate from the 1N point might indicate the pres-
ence of a diffuse initial signal consisting of simple Ys, dYs and bubbles; how-
ever, when the replication intermediates increase in size, they more closely 
resemble the Y structures. The secondary replication mechanism might also be 
a mechanism of recombination initiated by the invasion of a resectioned ssDNA 
end that originates from dsDNA breaks in the HPV18 genome into an intact 
homologous HPV molecule. The invasion of the resectioned ssDNA end results 
in the creation of D-loop structures and eventually the assembly of a unidirec-
tional replication fork. During bidirectional theta-replication, nicks can occur 
either in parental strands or in collapsed replication forks, which may disrupt 
bidirectional replication, thus enabling the switch to the unidirectional mode of 
replication. Unidirectional replication could then occur in either direction.  
 
 
5.4.4. The novel replication mechanism can initiate unidirectional 
replication forks in both directions 
To determine the polarity of replication forks initiated by different replication 
mechanisms, we resorted to in gelo digestion analysis. Using this type of analy-
sis, it is possible to determine whether the replication forks are moving via 
theta-replication or other mechanisms. 
At the beginning of bidirectional theta-replication, two replicative forks are 
formed. These forks begin to move in opposite directions from the origin until 
they meet in the region of termination. As shown in Ref. V, Fig. 6D, the repli-
52 
cation forks of the HPV18E8– genome are moving from the BglI restriction site 
to the termination area located between the PsyI and XmaJI restriction sites. The 
migration structures of these replication forks, following in gelo digestion, are 
demonstrated in Ref. V, Fig. 6C (Brewer et al., 1992, Gerhold et al., 2014, 
Ivessa, 2013). As is clearly seen from the in gelo analysis (Ref. V, Fig. 6A and 
B), in the XmaJI-BglI and BglI-PsyI fragments, the replication forks emerge 
bidirectionally (Ref. V, Fig. 6A and B, marked by black and red arrows). Repli-
cation forks moving in the opposite direction also appear in both fragments 
(Ref. V, Fig. 6A and B, marked by a white arrow). 
We cannot exclude the possibility that these signals result from the bidirec-
tional theta-replication of dimeric HPV18 molecules with only one active repli-
cation origin, as shown in diagram Ref. V, Fig. 6E. However, in the case of 
dimeric molecules replicating via theta-replication, the ratio of replication forks 
of the XmaJI-BglI and BglI-PsyI fragments in opposite directions would be 
equal. Our results indicated otherwise, although we did not quantify the signals 
(quantification is difficult for 2D gels and various hybridization probes were 
used to analyze the BglI-PsyI and BglI-XmaJI fragments). In the BglI-PsyI frag-
ment, the replication fork arising through bidirectional theta-replication is much 
more prevalent than the fork traveling in the opposite direction. In the BglI-
XmaJI fragment, the replication forks with opposing polarity appear to be of 
equal prevalence. These results indicate that although secondary unidirectional 
replication can be initiated in either direction, replication forks traveling clock-
wise seem to be preferred, at least at this time point.  
 
 
5.4.5. 2D neutral/neutral agarose gel electrophoresis analysis  
of subgenomic HPV18E8¯ fragments 
We also conducted a distinct restriction analysis of samples isolated from U2OS 
cells transfected with HPV18E8– minicircle using combinations of two line-
arizing enzymes (Cfr10I and Bpu1102I, Bpu1102I and PsyI, PsyI and XmaJI, 
XmaJI and Cfr10I). In this way, the HPV18E8– genome could be divided into 
two fragments of approximately 2 kbp and 6 kbp across the genome. These 
fragments were analyzed by 2D N/N gel electrophoresis, and four hybridization 
probes that recognized different genome regions were used (Ref. V, Fig. 5). 
As expected, we saw evidence of theta-replication intermediates in all of 
the smaller ca. 2 kbp genome fragments. All known interpretable structures 
were present: bubble, Y, dY, some of X arcs or termination arcs (Ref. V, Fig. 
5A and B, marked with black arrows).  
All of the large, ca. 6 kbp fragments yielded similar secondary replication 
intermediate patterns, which did not originate from 1N. The large branched 
molecules at the highest tip of theta signals, which likely represent late theta 
intermediates (incomplete, linked sister molecules), accumulated over time.  
Surprisingly, physical linkage of the joined molecules was detected along 
the entire length of the genome by the 2D method. Joined molecules seem to be 
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formed during DNA replication, and newly replicated sister molecules most 
likely remain linked. The existence of homologous-recombination-linked path-
ways for the replication HPV genomes and the formation of joined molecules 
can be resolved by analyzing the intermediates via atomic force microscopy 
(AFM) and electron microscopy (EM).  
Our study demonstrates that a novel replication mechanism is involved in 
HPV replication. However, we have not been able to visualize the replication 
intermediates of these replication modes using EM or AFM; thus, we can only 
speculate about the nature of these undefined replication intermediates. There-
fore, we cannot distinguish theta-replication from the second mechanism of 
replication to accurately characterize the later process. It is clear both that initial 
papillomavirus DNA replication starts with theta-replication and that theta-
replication is dependent on E1 and E2. We do not know whether the novel repli-
cation mechanism is dependent on these proteins. However, during initial virus 
DNA replication, not only monomeric but also oligomeric genomes are gener-
ated, and homologous recombination is clearly involved.  
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6. CONCLUSIONS 
1. Plasmids with hybrid origins, composed of a BPV1 E2 protein-dependent 
MME and mouse polyomavirus minimal origin were constructed. The repli-
cation enhancer and the stable maintenance functions were observed in the 
presence of the mouse polyomavirus large-T-antigen and the BPV1 E2 pro-
tein. The same functions can be provided by Epstein-Barr virus EBNA1 
protein when Family of Repeats (FR) was used instead of MME of BPV1. 
In the mouse fibroblast cell line COP5E2/Puro expressing polyomavirus 
large-T-antigen and BPV1 E2 protein, the reporter-protein encoding plas-
mids harboring hybrid origins were stably replicating and maintained for a 
long time; the episomal status of hybrid origin containing DNAs was moni-
tored for more than 3 months. The described chimeric system makes it pos-
sible to express a gene of interest for an extended time period in these cells. 
2. We have demonstrated that HPV genomes replicate efficiently in the human 
osteosarcoma cell line U2OS, which is capable of supporting the genome 
replication of many different subtypes (α-HPVs of high-risk HPV18 and 
HPV16; low-risk HPV6b and HPV11 and β-HPVs of HPV5 and HPV8). 
U2OS cells capable of supporting the maintenance of the HPV genomes 
provide a useful model system in which the mechanism and regulation of 
viral DNA replication during various phases of the viral life cycle, in-
cluding initial amplification (transient replication), stable maintenance and 
second amplification (vegetative replication), can be analyzed. 
3. We show the increasing prevalence of oligomeric HPV genomes in U2OS 
cells transfected with HPV DNA during the initial establishment stages, in 
stable maintenance and in the vegetative phase. We characterized these 
oligomers as episomal head-to-tail concatemeric molecules. HPV DNA 
obtained from patient samples has also been found to be oligomeric. We 
can conclude that HPV genome oligomerization is common for HPV infec-
tions in vivo. Homologous recombination-dependent replication might be 
involved in this process.  
4. Analysis of the replication intermediates arising during HPV18 genome 
replication showed that two types of replication intermediates arise during 
the transient amplification replication of HPV genomes. The intermediates 
are characteristic both of theta-replication and of a yet-unknown secondary 
replication mechanism. We propose that the second replication mechanism 
might involve homologous recombination.  
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SUMMARY IN ESTONIAN 
Papilloomiviiruse genoomi replikatsiooni ja säilumise uurimine 
2008. aastal jagati meditsiini Nobeli preemia kahele suuri avastusi teinud tead-
lasele, kellest üks oli Harald zur Hausen. Saksa viroloog zur Hausen tõestas, et 
inimese papilloomiviirused (HPVd) ei põhjusta ainult kahjutuid soolatüükaid, 
vaid nende nakkus inimesel võib viia emakakaelavähi tekkeni. Emakakaelavähk 
on naiste hulgas maailmas sageduselt teine onkoloogiline haigus.  
Papilloomiviirused on ümbriseta ja kaheahelalise DNA genoomiga viirused, 
mis on rangelt liigispetsiifilised. Siiski on inimest võimelised nakatama enam 
kui sada erinevat HPV tüüpi. Neist omakorda 18 tüüpi peetakse kõrge riskiga 
(kasvajaid tekitavateks) viirusteks. Kõige levinumad kõrge riskiga tüübid on 
HPV16 ja HPV18, mille vältimiseks on arendatud ka vaktsiinid. HPV vastane 
vaktsineerimine vähendab haigestumise tõenäosust vähemalt 70% võrra, kuid 
täielikku kaitset see paraku pakkuda ei suuda. Lisaks on olemasolevad vakt-
siinid mõeldud ainult haiguste ennetamiseks ja on seega kasutud viirusega juba 
nakatunud inimestele. Paraku ei ole veel välja töötatud ravimeid, mis oleksid 
võimelised papilloomiviiruse infektsiooni inimese organismist kõrvaldama. 
HPV on kõrge koespetsiifilisusega viirus ja nakatab epiteeli peamist raku-
tüüpi – keratinotsüüte. Nakatamiseks peab viirus sisenema naha epiteeli basaal-
kihi rakkudesse või genitaalide ja teiste organite limaskestade vastavatesse 
rakkudesse. Kuna HPV elustükkel sõltub täielikult keratinotsüütide diferent-
seerumisest, raskendab selle viiruse uurimist asjaolu, et uurimistöös kasutata-
vates rakulistes mudelsüsteemides on keratinotsüütide diferentseerumise käivi-
tamine väga keerukas. 
Antud töös kirjeldatakse inimese sääreluu kasvajast algatatud U2OS raku-
liinil põhinevat rakulist mudelsüsteemi, mida saab kasutada HPV genoomide 
replikatsiooni uurimiseks. Loodud mudelsüsteem on võimeline toetama erinevat 
tüüpi HPVde DNA replikatsiooni nii nagu see toimub viiruse loomuliku elu-
tsükli eri etappidel. Samuti võimaldab U2OS rakuliinil põhinev mudelsüsteem 
võrdlevalt uurida nii limaskesta sptesiifilisi kõrge riski (HPV16, HPV18), kui 
ka madala riski (HPV6b, HPV11) ning naha papilloomiviiruseid (HPV5, 
HPV8), mille uurimine teistes rakulistes mudelsüsteemides on seni olnud üsna 
keerukas. 
Uudse mudelsüsteemi abil oleme suutnud iseloomustada HPV DNA mole-
kulide erinevaid vorme, mis moodustuvad replikatsioonistükli eri etappidel. 
Viiruse genoomidega transfekteeritud U2OS rakuliinist ja patsientide koe-
proovidest pärineva viiruse DNA uurimisel selgus, et HPV genoom on võime-
line moodustama oligomeere – DNA molekule, mis sisaldavad mitut viiruse 
genoomi koopiat. Sellised multimeersed molekulid on tuvastatavad igas viiruse 
elutsükli etapis. 
Samuti näitasime, et HPV DNA replikatsiooni on kaasatud vähemalt kaks 
erinevat mehhanismi. Ühte neist on varasemalt juba kirjeldatud kui võimalikku 
papilloomiviiruste päriliku materjali paljundamise meetod – selleks on kahe-
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suunaline theta-replikatsioon. U2OS rakuliinil põhineva mudelsüsteemi abil 
tuvastasime aga veel teise, ühesuunalise replikatsioonimehhanismi, mis oletata-
valt põhineb homoloogse rekombinatsiooni kasutamisel ja mille roll HPV elu-
tsüklis on veel ebaselge. Selleks, et täpsemalt mõista uudse kirjeldatud mehha-
nismi iseärasusi, plaanime tulevikus kasutada elektron- või aatomjõumik-
roskoopiat. 
Lisaks ülaltoodule näidati käesolevas töös, et kõikide vajalike viiruseliste 
trans-faktorite juuresolekul on heteroloogsed originid, mis sisaldavad veise 
papilloomiviirusest (BPV1) või ka Epstein-Barr viirusest (EBV) pärinevaid 
segregatsioonielemente, võimelised tagama neid sisaldavate plasmiidide sta-
biilse säilumise. 
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